Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 132 | 2023 | 378 | 22.600 |
Why?
|
Anticholesteremic Agents | 95 | 2023 | 137 | 16.130 |
Why?
|
Cholesterol, LDL | 129 | 2023 | 222 | 14.920 |
Why?
|
Dyslipidemias | 58 | 2023 | 109 | 14.880 |
Why?
|
Cardiovascular Diseases | 90 | 2021 | 826 | 13.200 |
Why?
|
Hypercholesterolemia | 91 | 2021 | 161 | 12.620 |
Why?
|
Hypolipidemic Agents | 64 | 2020 | 102 | 11.640 |
Why?
|
Schizophrenia | 94 | 2021 | 463 | 9.520 |
Why?
|
Hypertriglyceridemia | 33 | 2023 | 67 | 8.650 |
Why?
|
Cholesterol, HDL | 81 | 2023 | 165 | 8.450 |
Why?
|
Fatty Acids, Omega-3 | 26 | 2021 | 49 | 7.550 |
Why?
|
Atherosclerosis | 26 | 2023 | 243 | 6.790 |
Why?
|
Coronary Disease | 50 | 2018 | 261 | 6.420 |
Why?
|
Coronary Artery Disease | 34 | 2021 | 344 | 5.820 |
Why?
|
Triglycerides | 64 | 2023 | 232 | 5.460 |
Why?
|
Schizophrenic Psychology | 61 | 2019 | 129 | 5.460 |
Why?
|
Lipids | 48 | 2019 | 269 | 5.030 |
Why?
|
Azetidines | 26 | 2013 | 36 | 5.020 |
Why?
|
Simvastatin | 44 | 2019 | 106 | 4.960 |
Why?
|
Antipsychotic Agents | 39 | 2019 | 123 | 4.920 |
Why?
|
Hyperlipidemias | 29 | 2014 | 95 | 4.520 |
Why?
|
Heptanoic Acids | 35 | 2014 | 72 | 4.160 |
Why?
|
Double-Blind Method | 130 | 2023 | 1816 | 4.060 |
Why?
|
Niacin | 25 | 2014 | 37 | 4.010 |
Why?
|
Fenofibrate | 18 | 2014 | 21 | 4.000 |
Why?
|
Cholesterol | 46 | 2023 | 356 | 3.970 |
Why?
|
Humans | 594 | 2023 | 86102 | 3.940 |
Why?
|
Drug Therapy, Combination | 67 | 2023 | 893 | 3.910 |
Why?
|
Pyrroles | 35 | 2014 | 184 | 3.870 |
Why?
|
Docosahexaenoic Acids | 16 | 2020 | 31 | 3.680 |
Why?
|
Fluorobenzenes | 24 | 2012 | 33 | 3.650 |
Why?
|
Risk Factors | 129 | 2020 | 5392 | 3.530 |
Why?
|
Cognition Disorders | 32 | 2015 | 236 | 3.330 |
Why?
|
Pyrimidines | 26 | 2012 | 370 | 3.260 |
Why?
|
Eicosapentaenoic Acid | 13 | 2020 | 17 | 3.190 |
Why?
|
Sulfonamides | 25 | 2012 | 298 | 3.140 |
Why?
|
Male | 342 | 2023 | 40834 | 2.970 |
Why?
|
Middle Aged | 256 | 2023 | 24935 | 2.900 |
Why?
|
Female | 330 | 2023 | 44359 | 2.720 |
Why?
|
Treatment Outcome | 113 | 2023 | 7933 | 2.680 |
Why?
|
Allylamine | 10 | 2013 | 11 | 2.680 |
Why?
|
Lipoproteins, LDL | 17 | 2016 | 83 | 2.620 |
Why?
|
Aged | 217 | 2020 | 18331 | 2.580 |
Why?
|
Biomarkers | 44 | 2021 | 1707 | 2.580 |
Why?
|
Cholesterol Ester Transfer Proteins | 19 | 2023 | 23 | 2.560 |
Why?
|
Diabetes Mellitus, Type 2 | 28 | 2017 | 1366 | 2.520 |
Why?
|
Ezetimibe | 27 | 2023 | 35 | 2.490 |
Why?
|
Lipoproteins | 27 | 2023 | 135 | 2.460 |
Why?
|
Indoles | 15 | 2019 | 317 | 2.330 |
Why?
|
Diabetes Mellitus | 21 | 2016 | 798 | 2.230 |
Why?
|
Metabolic Syndrome | 15 | 2011 | 141 | 2.100 |
Why?
|
Rhabdomyolysis | 7 | 2016 | 27 | 2.100 |
Why?
|
Hyperlipoproteinemia Type II | 9 | 2018 | 18 | 2.100 |
Why?
|
Adult | 203 | 2021 | 25559 | 2.080 |
Why?
|
Clinical Trials as Topic | 37 | 2021 | 1168 | 2.000 |
Why?
|
Serine Proteinase Inhibitors | 7 | 2019 | 28 | 1.970 |
Why?
|
Hypoglycemic Agents | 16 | 2015 | 377 | 1.930 |
Why?
|
Antibodies, Monoclonal | 11 | 2018 | 1376 | 1.890 |
Why?
|
Clofibric Acid | 10 | 2009 | 15 | 1.890 |
Why?
|
Randomized Controlled Trials as Topic | 31 | 2021 | 845 | 1.870 |
Why?
|
Primary Prevention | 8 | 2018 | 85 | 1.800 |
Why?
|
Psychiatric Status Rating Scales | 44 | 2018 | 486 | 1.750 |
Why?
|
Apolipoprotein A-I | 14 | 2015 | 71 | 1.740 |
Why?
|
Psychotic Disorders | 15 | 2018 | 183 | 1.680 |
Why?
|
Risperidone | 11 | 2012 | 23 | 1.680 |
Why?
|
Antibodies, Monoclonal, Humanized | 11 | 2023 | 927 | 1.630 |
Why?
|
Apolipoproteins B | 12 | 2014 | 38 | 1.620 |
Why?
|
Risk Assessment | 35 | 2019 | 2252 | 1.610 |
Why?
|
Intestinal Absorption | 8 | 2018 | 123 | 1.600 |
Why?
|
Tunica Intima | 10 | 2011 | 59 | 1.560 |
Why?
|
Dietary Supplements | 10 | 2020 | 128 | 1.470 |
Why?
|
Thiazolidinediones | 7 | 2012 | 82 | 1.470 |
Why?
|
Lipoproteins, HDL | 12 | 2016 | 96 | 1.450 |
Why?
|
Dementia | 16 | 2008 | 187 | 1.410 |
Why?
|
Molecular Targeted Therapy | 5 | 2018 | 266 | 1.400 |
Why?
|
Muscular Diseases | 10 | 2017 | 63 | 1.390 |
Why?
|
Alzheimer Disease | 33 | 2005 | 470 | 1.380 |
Why?
|
Lovastatin | 12 | 2005 | 29 | 1.360 |
Why?
|
Rosuvastatin Calcium | 26 | 2018 | 29 | 1.340 |
Why?
|
Diet, Fat-Restricted | 7 | 2020 | 30 | 1.340 |
Why?
|
Carotid Artery Diseases | 7 | 2015 | 97 | 1.330 |
Why?
|
Hyperlipoproteinemia Type I | 2 | 2018 | 2 | 1.270 |
Why?
|
Haloperidol | 12 | 2006 | 30 | 1.270 |
Why?
|
Carotid Arteries | 8 | 2014 | 127 | 1.260 |
Why?
|
Cost of Illness | 4 | 2018 | 150 | 1.250 |
Why?
|
Dose-Response Relationship, Drug | 43 | 2018 | 1958 | 1.240 |
Why?
|
Inflammation | 10 | 2020 | 910 | 1.230 |
Why?
|
Fatty Acids, Nonesterified | 7 | 2017 | 70 | 1.230 |
Why?
|
Practice Guidelines as Topic | 21 | 2021 | 1030 | 1.220 |
Why?
|
Nonprescription Drugs | 4 | 2018 | 15 | 1.220 |
Why?
|
Carboxylic Acids | 5 | 2018 | 17 | 1.200 |
Why?
|
Diabetic Angiopathies | 5 | 2011 | 62 | 1.200 |
Why?
|
Drug Administration Schedule | 28 | 2018 | 916 | 1.190 |
Why?
|
Fatty Acids, Omega-6 | 3 | 2018 | 9 | 1.190 |
Why?
|
Diabetes Complications | 9 | 2013 | 206 | 1.170 |
Why?
|
Quinolines | 5 | 2014 | 95 | 1.170 |
Why?
|
Esophageal Neoplasms | 3 | 2019 | 320 | 1.160 |
Why?
|
1-Alkyl-2-acetylglycerophosphocholine Esterase | 5 | 2011 | 35 | 1.130 |
Why?
|
Obesity | 15 | 2015 | 959 | 1.110 |
Why?
|
Drug-Related Side Effects and Adverse Reactions | 3 | 2019 | 199 | 1.070 |
Why?
|
Pravastatin | 9 | 2014 | 17 | 1.050 |
Why?
|
Proprotein Convertases | 4 | 2013 | 26 | 1.050 |
Why?
|
Time Factors | 47 | 2019 | 5198 | 1.030 |
Why?
|
Metabolic Diseases | 2 | 2018 | 48 | 1.030 |
Why?
|
Proprotein Convertase 9 | 10 | 2023 | 20 | 1.020 |
Why?
|
C-Reactive Protein | 16 | 2015 | 190 | 1.010 |
Why?
|
Follow-Up Studies | 42 | 2019 | 3613 | 1.000 |
Why?
|
Aged, 80 and over | 63 | 2018 | 6481 | 0.990 |
Why?
|
Carotid Intima-Media Thickness | 6 | 2015 | 38 | 0.990 |
Why?
|
Oxazolidinones | 6 | 2014 | 11 | 0.990 |
Why?
|
Adolescent | 58 | 2018 | 8967 | 0.970 |
Why?
|
Biological Availability | 11 | 2017 | 92 | 0.960 |
Why?
|
Neuropsychological Tests | 26 | 2015 | 502 | 0.960 |
Why?
|
Mental Disorders | 10 | 2018 | 371 | 0.960 |
Why?
|
Cardiology | 5 | 2012 | 123 | 0.950 |
Why?
|
Carotid Artery, Common | 3 | 2015 | 29 | 0.940 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 8 | 2019 | 2430 | 0.930 |
Why?
|
Severity of Illness Index | 30 | 2020 | 1794 | 0.920 |
Why?
|
Arteriosclerosis | 10 | 2008 | 113 | 0.890 |
Why?
|
Blood Glucose | 16 | 2015 | 873 | 0.890 |
Why?
|
Hospitalization | 23 | 2016 | 843 | 0.890 |
Why?
|
Risk | 17 | 2018 | 673 | 0.870 |
Why?
|
Carrier Proteins | 7 | 2014 | 672 | 0.840 |
Why?
|
Adenocarcinoma | 3 | 2019 | 1160 | 0.840 |
Why?
|
Postmenopause | 12 | 2005 | 97 | 0.830 |
Why?
|
Drug Combinations | 14 | 2014 | 222 | 0.830 |
Why?
|
Diet | 13 | 2017 | 442 | 0.810 |
Why?
|
Homovanillic Acid | 12 | 1994 | 35 | 0.810 |
Why?
|
Colchicine | 1 | 2021 | 23 | 0.800 |
Why?
|
Intelligence | 6 | 2015 | 71 | 0.790 |
Why?
|
Sterols | 2 | 2018 | 16 | 0.780 |
Why?
|
Kidney Failure, Chronic | 3 | 2020 | 509 | 0.780 |
Why?
|
United States | 35 | 2020 | 6628 | 0.770 |
Why?
|
Esters | 5 | 2017 | 29 | 0.760 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 2 | 2020 | 240 | 0.760 |
Why?
|
Flushing | 6 | 2009 | 7 | 0.750 |
Why?
|
Chemical and Drug Induced Liver Injury | 4 | 2016 | 62 | 0.750 |
Why?
|
Gemfibrozil | 5 | 2012 | 8 | 0.740 |
Why?
|
Cohort Studies | 25 | 2017 | 2759 | 0.740 |
Why?
|
Anemia | 2 | 2020 | 128 | 0.740 |
Why?
|
Israel | 18 | 2017 | 55 | 0.730 |
Why?
|
Vitamins | 5 | 2014 | 81 | 0.710 |
Why?
|
Suicide | 3 | 2016 | 139 | 0.710 |
Why?
|
Lipoprotein(a) | 6 | 2020 | 28 | 0.710 |
Why?
|
Bile Acids and Salts | 4 | 2011 | 58 | 0.700 |
Why?
|
Kidney Diseases | 5 | 2018 | 418 | 0.690 |
Why?
|
Tunica Media | 5 | 2011 | 16 | 0.690 |
Why?
|
Prospective Studies | 29 | 2019 | 4190 | 0.690 |
Why?
|
Dietary Fiber | 8 | 2007 | 43 | 0.680 |
Why?
|
Nutritional Sciences | 1 | 2018 | 12 | 0.680 |
Why?
|
Colesevelam Hydrochloride | 10 | 2013 | 11 | 0.680 |
Why?
|
Renal Dialysis | 2 | 2020 | 354 | 0.660 |
Why?
|
Young Adult | 26 | 2019 | 5960 | 0.660 |
Why?
|
Fasting | 7 | 2020 | 161 | 0.660 |
Why?
|
Predictive Value of Tests | 14 | 2019 | 1671 | 0.660 |
Why?
|
Ibuprofen | 2 | 2018 | 27 | 0.650 |
Why?
|
Fatty Acids, Monounsaturated | 6 | 2005 | 14 | 0.650 |
Why?
|
Naproxen | 1 | 2018 | 13 | 0.640 |
Why?
|
Comorbidity | 18 | 2019 | 941 | 0.640 |
Why?
|
Anti-Obesity Agents | 2 | 2013 | 14 | 0.640 |
Why?
|
Retrospective Studies | 27 | 2019 | 8406 | 0.640 |
Why?
|
Sulfonylurea Compounds | 5 | 2011 | 62 | 0.630 |
Why?
|
Military Personnel | 6 | 2017 | 84 | 0.630 |
Why?
|
Acetaminophen | 1 | 2018 | 54 | 0.630 |
Why?
|
Estrogen Replacement Therapy | 8 | 2005 | 45 | 0.630 |
Why?
|
Glycoproteins | 5 | 2014 | 234 | 0.620 |
Why?
|
Research | 2 | 2018 | 252 | 0.620 |
Why?
|
Adverse Drug Reaction Reporting Systems | 4 | 2006 | 22 | 0.620 |
Why?
|
Body Weight | 11 | 2014 | 459 | 0.610 |
Why?
|
Arthralgia | 1 | 2017 | 36 | 0.610 |
Why?
|
Chronic Disease | 25 | 2013 | 966 | 0.600 |
Why?
|
Fat Substitutes | 3 | 2014 | 3 | 0.600 |
Why?
|
Disease Management | 2 | 2018 | 327 | 0.590 |
Why?
|
Analgesics | 1 | 2018 | 119 | 0.590 |
Why?
|
Heart Diseases | 3 | 2018 | 290 | 0.590 |
Why?
|
Twins, Monozygotic | 1 | 2016 | 57 | 0.580 |
Why?
|
Blood Pressure | 13 | 2015 | 1141 | 0.570 |
Why?
|
Patient Selection | 10 | 2013 | 685 | 0.570 |
Why?
|
Indians, North American | 8 | 2013 | 48 | 0.570 |
Why?
|
Patient Discharge | 2 | 2015 | 296 | 0.570 |
Why?
|
Phytosterols | 4 | 2006 | 6 | 0.560 |
Why?
|
Registries | 11 | 2016 | 701 | 0.560 |
Why?
|
Medical Laboratory Science | 2 | 2006 | 7 | 0.560 |
Why?
|
Fatty Acids | 7 | 2018 | 129 | 0.550 |
Why?
|
Age Factors | 26 | 2019 | 1842 | 0.550 |
Why?
|
Actins | 8 | 2015 | 448 | 0.550 |
Why?
|
Dietary Fats | 7 | 2018 | 134 | 0.540 |
Why?
|
Psychometrics | 16 | 2017 | 327 | 0.540 |
Why?
|
Serine Endopeptidases | 3 | 2013 | 145 | 0.540 |
Why?
|
Area Under Curve | 9 | 2020 | 334 | 0.540 |
Why?
|
Animals | 51 | 2020 | 26469 | 0.540 |
Why?
|
Biological Transport | 3 | 2013 | 396 | 0.540 |
Why?
|
Prevalence | 14 | 2016 | 1238 | 0.540 |
Why?
|
Incretins | 2 | 2014 | 14 | 0.540 |
Why?
|
Oligonucleotides | 2 | 2013 | 92 | 0.530 |
Why?
|
Beverages | 2 | 2009 | 17 | 0.530 |
Why?
|
Comprehensive Health Care | 1 | 2015 | 13 | 0.530 |
Why?
|
Stomach Neoplasms | 1 | 2018 | 265 | 0.530 |
Why?
|
Glucagon-Like Peptide 1 | 2 | 2014 | 48 | 0.530 |
Why?
|
Insulin Resistance | 7 | 2013 | 377 | 0.520 |
Why?
|
Surveys and Questionnaires | 9 | 2018 | 2493 | 0.520 |
Why?
|
Adrenergic beta-2 Receptor Agonists | 1 | 2015 | 23 | 0.520 |
Why?
|
Intestines | 1 | 2018 | 407 | 0.520 |
Why?
|
Glycerides | 1 | 2014 | 17 | 0.510 |
Why?
|
Patient Compliance | 9 | 2014 | 226 | 0.500 |
Why?
|
Insulin | 9 | 2015 | 1159 | 0.500 |
Why?
|
Dipeptidyl-Peptidase IV Inhibitors | 1 | 2014 | 14 | 0.500 |
Why?
|
Cross-Over Studies | 11 | 2020 | 397 | 0.500 |
Why?
|
Pyridines | 6 | 2012 | 309 | 0.500 |
Why?
|
Precision Medicine | 1 | 2018 | 393 | 0.490 |
Why?
|
Blood Chemical Analysis | 4 | 2012 | 42 | 0.490 |
Why?
|
Program Evaluation | 2 | 2006 | 297 | 0.490 |
Why?
|
Apolipoprotein C-III | 4 | 2020 | 8 | 0.490 |
Why?
|
Disease Progression | 12 | 2016 | 1526 | 0.480 |
Why?
|
Genetic Variation | 4 | 2019 | 1347 | 0.480 |
Why?
|
Medical Records Systems, Computerized | 3 | 2009 | 40 | 0.480 |
Why?
|
Stroke | 6 | 2018 | 956 | 0.480 |
Why?
|
Secondary Prevention | 5 | 2011 | 162 | 0.480 |
Why?
|
Longitudinal Studies | 17 | 2017 | 1011 | 0.470 |
Why?
|
Cholinesterase Inhibitors | 5 | 2004 | 45 | 0.470 |
Why?
|
Aging | 7 | 2007 | 689 | 0.470 |
Why?
|
Dopamine Antagonists | 2 | 2012 | 35 | 0.460 |
Why?
|
Algorithms | 12 | 2020 | 1827 | 0.460 |
Why?
|
Phentermine | 1 | 2013 | 4 | 0.460 |
Why?
|
Hydroxymethylglutaryl CoA Reductases | 4 | 2002 | 16 | 0.460 |
Why?
|
Fructose | 1 | 2013 | 35 | 0.450 |
Why?
|
Immunotherapy | 1 | 2018 | 626 | 0.450 |
Why?
|
Social Adjustment | 6 | 2019 | 46 | 0.450 |
Why?
|
GABA Agonists | 1 | 2012 | 20 | 0.440 |
Why?
|
Lipid Metabolism | 4 | 2015 | 196 | 0.440 |
Why?
|
Delayed-Action Preparations | 10 | 2013 | 116 | 0.440 |
Why?
|
Cytomegalovirus Retinitis | 2 | 2002 | 7 | 0.440 |
Why?
|
Hypertension | 10 | 2008 | 1137 | 0.440 |
Why?
|
Sex Factors | 13 | 2019 | 1053 | 0.440 |
Why?
|
AIDS-Related Opportunistic Infections | 2 | 2002 | 33 | 0.430 |
Why?
|
Incidence | 14 | 2018 | 1566 | 0.430 |
Why?
|
gamma-Aminobutyric Acid | 1 | 2012 | 83 | 0.430 |
Why?
|
Quality of Life | 5 | 2017 | 1572 | 0.430 |
Why?
|
Risk Reduction Behavior | 4 | 2009 | 98 | 0.420 |
Why?
|
Coronary Vessels | 5 | 2008 | 174 | 0.420 |
Why?
|
Health Surveys | 3 | 2013 | 238 | 0.420 |
Why?
|
Granulocyte Colony-Stimulating Factor | 2 | 2002 | 164 | 0.410 |
Why?
|
Population Surveillance | 6 | 2006 | 219 | 0.410 |
Why?
|
Estradiol | 4 | 2019 | 249 | 0.400 |
Why?
|
Receptors, Cytoplasmic and Nuclear | 2 | 2009 | 122 | 0.400 |
Why?
|
Olive Oil | 5 | 2017 | 8 | 0.400 |
Why?
|
Patient Admission | 6 | 2017 | 112 | 0.400 |
Why?
|
Bipolar Disorder | 3 | 2012 | 377 | 0.400 |
Why?
|
Calcinosis | 2 | 2010 | 224 | 0.400 |
Why?
|
Cell Movement | 5 | 2015 | 754 | 0.390 |
Why?
|
Prognosis | 18 | 2013 | 3660 | 0.390 |
Why?
|
Practice Patterns, Physicians' | 3 | 2009 | 578 | 0.390 |
Why?
|
Cardiovascular System | 1 | 2011 | 71 | 0.390 |
Why?
|
Drug Interactions | 9 | 2017 | 248 | 0.390 |
Why?
|
Central Nervous System Infections | 1 | 2010 | 3 | 0.390 |
Why?
|
Farnesyl-Diphosphate Farnesyltransferase | 2 | 2009 | 5 | 0.390 |
Why?
|
Cell Polarity | 3 | 2016 | 114 | 0.390 |
Why?
|
Adaptation, Psychological | 6 | 2019 | 157 | 0.390 |
Why?
|
Administration, Oral | 11 | 2013 | 683 | 0.390 |
Why?
|
Apolipoproteins | 11 | 2023 | 38 | 0.380 |
Why?
|
Paclitaxel | 3 | 1997 | 460 | 0.380 |
Why?
|
Child, Hospitalized | 1 | 2010 | 33 | 0.370 |
Why?
|
Regression Analysis | 8 | 2015 | 595 | 0.370 |
Why?
|
Safety | 8 | 2017 | 152 | 0.370 |
Why?
|
Cholesterol, VLDL | 6 | 2015 | 14 | 0.370 |
Why?
|
Lythraceae | 1 | 2009 | 1 | 0.370 |
Why?
|
Betaine | 1 | 2009 | 4 | 0.370 |
Why?
|
Vasodilator Agents | 4 | 2015 | 152 | 0.360 |
Why?
|
Nicotine | 3 | 2004 | 193 | 0.360 |
Why?
|
Health Care Costs | 2 | 2010 | 237 | 0.360 |
Why?
|
Homocysteine | 1 | 2009 | 29 | 0.360 |
Why?
|
Piperidines | 3 | 2009 | 181 | 0.360 |
Why?
|
Microtubules | 3 | 2015 | 117 | 0.350 |
Why?
|
Physician's Role | 1 | 2011 | 179 | 0.350 |
Why?
|
Psyllium | 3 | 2000 | 3 | 0.350 |
Why?
|
Quinazolines | 1 | 2011 | 218 | 0.350 |
Why?
|
Body Composition | 3 | 2007 | 68 | 0.350 |
Why?
|
Phytotherapy | 2 | 2011 | 132 | 0.350 |
Why?
|
Intestinal Mucosa | 2 | 2014 | 788 | 0.350 |
Why?
|
Intelligence Tests | 2 | 2006 | 38 | 0.350 |
Why?
|
Body Mass Index | 10 | 2016 | 767 | 0.340 |
Why?
|
Refractive Errors | 1 | 2008 | 4 | 0.340 |
Why?
|
Genetic Therapy | 3 | 2015 | 342 | 0.340 |
Why?
|
Organophosphorus Compounds | 1 | 2009 | 55 | 0.340 |
Why?
|
Forecasting | 4 | 2012 | 303 | 0.340 |
Why?
|
Evidence-Based Medicine | 5 | 2011 | 429 | 0.340 |
Why?
|
Focal Adhesions | 3 | 2014 | 69 | 0.340 |
Why?
|
Ultrasonography, Interventional | 2 | 2008 | 121 | 0.340 |
Why?
|
Aspirin | 3 | 2021 | 155 | 0.340 |
Why?
|
Pancreatitis | 2 | 2020 | 87 | 0.340 |
Why?
|
Spironolactone | 1 | 2008 | 23 | 0.340 |
Why?
|
Cognition | 9 | 2018 | 570 | 0.330 |
Why?
|
Health Expenditures | 1 | 2010 | 86 | 0.330 |
Why?
|
Glucans | 2 | 2003 | 9 | 0.330 |
Why?
|
Analysis of Variance | 16 | 2013 | 912 | 0.330 |
Why?
|
Carotid Stenosis | 1 | 2009 | 112 | 0.330 |
Why?
|
Benzamides | 1 | 2009 | 225 | 0.330 |
Why?
|
Mineralocorticoid Receptor Antagonists | 1 | 2008 | 59 | 0.320 |
Why?
|
Patient Education as Topic | 3 | 2002 | 351 | 0.320 |
Why?
|
Edible Grain | 3 | 2007 | 9 | 0.320 |
Why?
|
Lipid Metabolism Disorders | 2 | 2021 | 2 | 0.320 |
Why?
|
Myocardial Ischemia | 2 | 2009 | 159 | 0.310 |
Why?
|
Circadian Rhythm | 4 | 2008 | 303 | 0.310 |
Why?
|
Albuminuria | 1 | 2008 | 153 | 0.310 |
Why?
|
Carotid Artery, Internal | 1 | 2007 | 69 | 0.310 |
Why?
|
Clinical Trials, Phase III as Topic | 5 | 2019 | 168 | 0.310 |
Why?
|
Social Class | 2 | 2007 | 127 | 0.310 |
Why?
|
Enzyme Inhibitors | 6 | 2009 | 632 | 0.310 |
Why?
|
Smoking | 5 | 2004 | 605 | 0.310 |
Why?
|
Fish Oils | 4 | 2008 | 11 | 0.310 |
Why?
|
Benzimidazoles | 3 | 2014 | 140 | 0.300 |
Why?
|
Glycemic Index | 1 | 2007 | 10 | 0.300 |
Why?
|
Cholagogues and Choleretics | 3 | 2006 | 10 | 0.300 |
Why?
|
Geriatric Assessment | 7 | 2005 | 166 | 0.300 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 1 | 2008 | 231 | 0.300 |
Why?
|
Drug Prescriptions | 3 | 2016 | 141 | 0.300 |
Why?
|
Cross-Sectional Studies | 11 | 2017 | 1608 | 0.300 |
Why?
|
Prostatic Neoplasms | 2 | 2019 | 1703 | 0.300 |
Why?
|
Cholelithiasis | 1 | 2006 | 34 | 0.300 |
Why?
|
Isoxazoles | 1 | 2007 | 77 | 0.300 |
Why?
|
Membrane Glycoproteins | 1 | 2009 | 428 | 0.300 |
Why?
|
Plasminogen Activator Inhibitor 1 | 1 | 2006 | 36 | 0.290 |
Why?
|
Smoking Cessation | 2 | 1999 | 230 | 0.290 |
Why?
|
Cell Adhesion | 5 | 2015 | 418 | 0.280 |
Why?
|
Antibodies, Bacterial | 4 | 2013 | 95 | 0.280 |
Why?
|
Reference Values | 12 | 2009 | 673 | 0.280 |
Why?
|
Genetic Predisposition to Disease | 7 | 2019 | 2257 | 0.280 |
Why?
|
Prediabetic State | 4 | 2015 | 39 | 0.280 |
Why?
|
Age of Onset | 4 | 2019 | 306 | 0.280 |
Why?
|
Drug Compounding | 2 | 2016 | 77 | 0.270 |
Why?
|
Sterol O-Acyltransferase | 4 | 2011 | 10 | 0.270 |
Why?
|
Ovarian Neoplasms | 3 | 1997 | 737 | 0.270 |
Why?
|
Pneumococcal Infections | 4 | 1996 | 46 | 0.270 |
Why?
|
Dietary Fats, Unsaturated | 4 | 2002 | 7 | 0.270 |
Why?
|
Cytoskeleton | 3 | 2016 | 190 | 0.270 |
Why?
|
Cholesterol Esters | 2 | 2003 | 12 | 0.270 |
Why?
|
Blood Platelets | 2 | 2017 | 149 | 0.270 |
Why?
|
Drug Delivery Systems | 1 | 2007 | 177 | 0.270 |
Why?
|
Sensitivity and Specificity | 9 | 2018 | 1987 | 0.260 |
Why?
|
Estrogens | 3 | 2019 | 197 | 0.260 |
Why?
|
Lactones | 3 | 2000 | 28 | 0.260 |
Why?
|
Vaccines, Synthetic | 2 | 2003 | 55 | 0.260 |
Why?
|
Proteinuria | 2 | 2006 | 107 | 0.260 |
Why?
|
Fluorescent Dyes | 3 | 2015 | 242 | 0.260 |
Why?
|
Phosphatidylcholine-Sterol O-Acyltransferase | 1 | 2004 | 6 | 0.260 |
Why?
|
Dopamine | 9 | 1994 | 275 | 0.260 |
Why?
|
Survival Rate | 8 | 2011 | 1855 | 0.260 |
Why?
|
Intermediate Filaments | 2 | 2015 | 16 | 0.260 |
Why?
|
Adipose Tissue | 4 | 2009 | 240 | 0.260 |
Why?
|
Vinculin | 2 | 2015 | 9 | 0.260 |
Why?
|
India | 3 | 2016 | 118 | 0.250 |
Why?
|
Vimentin | 2 | 2015 | 44 | 0.250 |
Why?
|
Maximum Tolerated Dose | 2 | 2018 | 270 | 0.250 |
Why?
|
Mental Status Schedule | 5 | 1997 | 25 | 0.250 |
Why?
|
United States Food and Drug Administration | 5 | 2008 | 127 | 0.250 |
Why?
|
Hospitals, Psychiatric | 4 | 2016 | 22 | 0.250 |
Why?
|
Electrolytes | 2 | 2004 | 52 | 0.250 |
Why?
|
Tumor Lysis Syndrome | 1 | 2004 | 9 | 0.250 |
Why?
|
Apolipoprotein B-100 | 4 | 2018 | 12 | 0.250 |
Why?
|
Skin | 1 | 2008 | 554 | 0.250 |
Why?
|
Consensus | 4 | 2020 | 332 | 0.250 |
Why?
|
Interleukin-6 | 3 | 2020 | 254 | 0.250 |
Why?
|
Terminology as Topic | 1 | 2006 | 217 | 0.250 |
Why?
|
Chlamydophila pneumoniae | 3 | 2013 | 12 | 0.250 |
Why?
|
Research Design | 6 | 2018 | 593 | 0.250 |
Why?
|
Dicarboxylic Acids | 2 | 2014 | 22 | 0.250 |
Why?
|
Peptides | 3 | 2020 | 639 | 0.240 |
Why?
|
Developmental Disabilities | 1 | 2005 | 194 | 0.240 |
Why?
|
Nootropic Agents | 1 | 2004 | 10 | 0.240 |
Why?
|
Frontal Lobe | 6 | 2006 | 130 | 0.240 |
Why?
|
Phospholipases A2 | 2 | 2015 | 44 | 0.240 |
Why?
|
Endocrinologists | 3 | 2020 | 4 | 0.240 |
Why?
|
Eggs | 1 | 2003 | 12 | 0.240 |
Why?
|
Food, Fortified | 1 | 2003 | 13 | 0.240 |
Why?
|
Peripheral Arterial Disease | 2 | 2018 | 84 | 0.240 |
Why?
|
DNA Copy Number Variations | 2 | 2018 | 171 | 0.240 |
Why?
|
Indans | 1 | 2004 | 31 | 0.240 |
Why?
|
Child | 17 | 2017 | 6907 | 0.240 |
Why?
|
Lipase | 2 | 2004 | 22 | 0.240 |
Why?
|
Alaska | 12 | 2013 | 17 | 0.240 |
Why?
|
Reproducibility of Results | 12 | 2017 | 2698 | 0.230 |
Why?
|
Liver | 6 | 2015 | 1229 | 0.230 |
Why?
|
Acute Kidney Injury | 2 | 2004 | 294 | 0.230 |
Why?
|
Survival Analysis | 5 | 2018 | 1536 | 0.230 |
Why?
|
Dangerous Behavior | 1 | 2003 | 4 | 0.230 |
Why?
|
Societies, Medical | 5 | 2021 | 571 | 0.230 |
Why?
|
Phenotype | 6 | 2019 | 2369 | 0.230 |
Why?
|
Adolescent Behavior | 1 | 2004 | 106 | 0.230 |
Why?
|
Multivariate Analysis | 6 | 2013 | 997 | 0.230 |
Why?
|
Half-Life | 5 | 2020 | 96 | 0.230 |
Why?
|
Language Disorders | 1 | 2002 | 9 | 0.230 |
Why?
|
Luminescent Proteins | 2 | 2015 | 144 | 0.230 |
Why?
|
Antihypertensive Agents | 2 | 2007 | 520 | 0.230 |
Why?
|
DNA-Binding Proteins | 1 | 2009 | 1204 | 0.230 |
Why?
|
Meat | 2 | 2000 | 26 | 0.220 |
Why?
|
Activities of Daily Living | 6 | 2017 | 201 | 0.220 |
Why?
|
Estrogens, Conjugated (USP) | 6 | 2002 | 16 | 0.220 |
Why?
|
Guideline Adherence | 2 | 2002 | 222 | 0.220 |
Why?
|
Autoimmunity | 1 | 2004 | 159 | 0.220 |
Why?
|
Food | 2 | 2001 | 85 | 0.220 |
Why?
|
Muscle, Skeletal | 1 | 2005 | 448 | 0.220 |
Why?
|
Databases, Factual | 6 | 2015 | 807 | 0.220 |
Why?
|
Healthy Volunteers | 3 | 2017 | 141 | 0.220 |
Why?
|
Societies, Scientific | 2 | 2013 | 43 | 0.220 |
Why?
|
Brain Ischemia | 1 | 2007 | 396 | 0.220 |
Why?
|
Integrins | 2 | 2014 | 76 | 0.210 |
Why?
|
Institutionalization | 3 | 2002 | 5 | 0.210 |
Why?
|
Chlamydia Infections | 2 | 2000 | 25 | 0.210 |
Why?
|
Proportional Hazards Models | 9 | 2017 | 857 | 0.210 |
Why?
|
Autoantibodies | 1 | 2003 | 266 | 0.210 |
Why?
|
Mental Recall | 5 | 1997 | 157 | 0.210 |
Why?
|
Anticoagulants | 4 | 2020 | 403 | 0.210 |
Why?
|
Norethindrone | 2 | 2002 | 12 | 0.210 |
Why?
|
Hyperlipidemia, Familial Combined | 2 | 2001 | 5 | 0.210 |
Why?
|
Diet Records | 4 | 2003 | 19 | 0.210 |
Why?
|
Ultrasonography | 6 | 2011 | 694 | 0.210 |
Why?
|
Calcium Channel Blockers | 3 | 2003 | 203 | 0.210 |
Why?
|
Death, Sudden, Cardiac | 1 | 2002 | 45 | 0.210 |
Why?
|
Odds Ratio | 3 | 2012 | 677 | 0.210 |
Why?
|
Clozapine | 4 | 1994 | 9 | 0.200 |
Why?
|
Ligands | 2 | 2020 | 433 | 0.200 |
Why?
|
HIV-1 | 1 | 2002 | 163 | 0.200 |
Why?
|
Parasympathomimetics | 2 | 1991 | 8 | 0.200 |
Why?
|
Apolipoprotein C-II | 2 | 2020 | 2 | 0.200 |
Why?
|
RNA, Viral | 1 | 2002 | 327 | 0.200 |
Why?
|
Life Style | 6 | 2013 | 188 | 0.200 |
Why?
|
Placebos | 10 | 2021 | 218 | 0.200 |
Why?
|
Cyclophosphamide | 3 | 1997 | 299 | 0.200 |
Why?
|
Corn Oil | 1 | 2020 | 3 | 0.200 |
Why?
|
Drug Evaluation | 1 | 2001 | 141 | 0.200 |
Why?
|
Hepcidins | 1 | 2020 | 4 | 0.200 |
Why?
|
Delusions | 2 | 2000 | 11 | 0.200 |
Why?
|
Health Education | 2 | 2014 | 100 | 0.200 |
Why?
|
Hematinics | 1 | 2020 | 11 | 0.200 |
Why?
|
Mathematics | 3 | 2012 | 190 | 0.190 |
Why?
|
Tablets | 5 | 2009 | 116 | 0.190 |
Why?
|
Social Behavior | 3 | 2019 | 294 | 0.190 |
Why?
|
Sulfhydryl Compounds | 2 | 2011 | 69 | 0.190 |
Why?
|
Digestive System | 2 | 2000 | 42 | 0.190 |
Why?
|
Dehydroepiandrosterone | 1 | 2000 | 51 | 0.190 |
Why?
|
Kidney | 1 | 2006 | 1236 | 0.190 |
Why?
|
Thrombosis | 2 | 2020 | 296 | 0.190 |
Why?
|
Case-Control Studies | 6 | 2016 | 1796 | 0.190 |
Why?
|
Cross-Cultural Comparison | 3 | 2009 | 34 | 0.190 |
Why?
|
Dyskinesia, Drug-Induced | 4 | 2007 | 19 | 0.190 |
Why?
|
Outpatients | 1 | 2021 | 94 | 0.190 |
Why?
|
Early Diagnosis | 2 | 2018 | 131 | 0.190 |
Why?
|
Plant Oils | 2 | 2013 | 9 | 0.190 |
Why?
|
Warfarin | 2 | 2017 | 103 | 0.190 |
Why?
|
Serum Albumin | 1 | 2020 | 130 | 0.190 |
Why?
|
Oocyte Donation | 1 | 1999 | 3 | 0.190 |
Why?
|
Benzaldehydes | 2 | 2011 | 4 | 0.180 |
Why?
|
Lipoproteins, VLDL | 5 | 2016 | 37 | 0.180 |
Why?
|
MMPI | 1 | 1999 | 11 | 0.180 |
Why?
|
Oximes | 2 | 2011 | 15 | 0.180 |
Why?
|
Cyclosporine | 2 | 2003 | 234 | 0.180 |
Why?
|
Heterozygote | 3 | 2018 | 365 | 0.180 |
Why?
|
Educational Status | 5 | 2008 | 187 | 0.180 |
Why?
|
Cisplatin | 3 | 1997 | 604 | 0.180 |
Why?
|
Heart Valve Prosthesis Implantation | 2 | 2013 | 166 | 0.180 |
Why?
|
Drug Discovery | 2 | 2011 | 103 | 0.180 |
Why?
|
Myosin Type II | 3 | 2015 | 48 | 0.180 |
Why?
|
Diagnostic and Statistical Manual of Mental Disorders | 3 | 2010 | 216 | 0.180 |
Why?
|
Internet | 2 | 2018 | 309 | 0.180 |
Why?
|
ATP-Binding Cassette Transporters | 2 | 2011 | 141 | 0.180 |
Why?
|
Inulin | 1 | 1999 | 17 | 0.180 |
Why?
|
Postprandial Period | 3 | 2014 | 47 | 0.180 |
Why?
|
Inflammation Mediators | 3 | 2009 | 154 | 0.180 |
Why?
|
Streptococcus pneumoniae | 5 | 1996 | 48 | 0.180 |
Why?
|
Cytochrome P-450 Enzyme System | 1 | 2000 | 79 | 0.180 |
Why?
|
Mixed Function Oxygenases | 1 | 2000 | 68 | 0.180 |
Why?
|
Fibric Acids | 2 | 2016 | 2 | 0.180 |
Why?
|
Problem Solving | 2 | 2012 | 54 | 0.180 |
Why?
|
Food, Formulated | 2 | 1996 | 24 | 0.180 |
Why?
|
Depressive Disorder | 4 | 2002 | 218 | 0.180 |
Why?
|
Memory Disorders | 3 | 2015 | 69 | 0.170 |
Why?
|
Fatty Acids, Unsaturated | 3 | 2013 | 28 | 0.170 |
Why?
|
Cholesterol, Dietary | 4 | 2003 | 27 | 0.170 |
Why?
|
Least-Squares Analysis | 4 | 2014 | 48 | 0.170 |
Why?
|
Extracellular Matrix | 3 | 2015 | 231 | 0.170 |
Why?
|
Mass Screening | 3 | 2017 | 615 | 0.170 |
Why?
|
Minocycline | 1 | 2018 | 15 | 0.170 |
Why?
|
Nutrition Policy | 1 | 2018 | 12 | 0.170 |
Why?
|
Models, Biological | 5 | 2015 | 1746 | 0.170 |
Why?
|
Intra-Abdominal Fat | 2 | 2009 | 29 | 0.170 |
Why?
|
Isoenzymes | 3 | 2006 | 271 | 0.170 |
Why?
|
International Classification of Diseases | 3 | 2009 | 67 | 0.170 |
Why?
|
Mutation | 9 | 2018 | 3948 | 0.170 |
Why?
|
Serotonin 5-HT2 Receptor Antagonists | 1 | 2018 | 7 | 0.170 |
Why?
|
Mendelian Randomization Analysis | 1 | 2018 | 42 | 0.170 |
Why?
|
Receptors, sigma | 1 | 2018 | 6 | 0.170 |
Why?
|
Nutritional Requirements | 1 | 1998 | 17 | 0.160 |
Why?
|
Antiviral Agents | 1 | 2002 | 506 | 0.160 |
Why?
|
Combined Modality Therapy | 5 | 2013 | 1661 | 0.160 |
Why?
|
Food Labeling | 1 | 1998 | 8 | 0.160 |
Why?
|
Creatine Kinase | 5 | 2007 | 52 | 0.160 |
Why?
|
Fruit | 1 | 1998 | 75 | 0.160 |
Why?
|
Esophagogastric Junction | 1 | 2018 | 34 | 0.160 |
Why?
|
Oxazepines | 2 | 2009 | 4 | 0.160 |
Why?
|
Apolipoproteins E | 2 | 2005 | 129 | 0.160 |
Why?
|
Lipid Peroxidation | 2 | 2009 | 44 | 0.160 |
Why?
|
Clinical Trials, Phase II as Topic | 3 | 2014 | 173 | 0.160 |
Why?
|
Orientation | 2 | 1995 | 119 | 0.160 |
Why?
|
Alanine Transaminase | 3 | 2010 | 73 | 0.160 |
Why?
|
Indoleacetic Acids | 2 | 2009 | 10 | 0.160 |
Why?
|
Circulating Tumor DNA | 1 | 2018 | 37 | 0.160 |
Why?
|
Drug Labeling | 1 | 2018 | 41 | 0.160 |
Why?
|
Genome-Wide Association Study | 4 | 2018 | 1602 | 0.160 |
Why?
|
Myocardium | 3 | 2014 | 527 | 0.160 |
Why?
|
Nicotinic Agonists | 1 | 1998 | 72 | 0.160 |
Why?
|
Weight Loss | 4 | 2002 | 229 | 0.160 |
Why?
|
Logistic Models | 6 | 2015 | 1184 | 0.160 |
Why?
|
Piperazines | 4 | 1994 | 271 | 0.160 |
Why?
|
Fibroblasts | 3 | 2015 | 729 | 0.160 |
Why?
|
DNA Mutational Analysis | 2 | 2018 | 526 | 0.160 |
Why?
|
Asymptomatic Diseases | 1 | 2017 | 40 | 0.160 |
Why?
|
Verbal Behavior | 2 | 1997 | 32 | 0.160 |
Why?
|
Bezafibrate | 2 | 2009 | 5 | 0.150 |
Why?
|
Hospitals, State | 1 | 1997 | 2 | 0.150 |
Why?
|
Chylomicrons | 1 | 2017 | 12 | 0.150 |
Why?
|
Geriatric Psychiatry | 1 | 1997 | 18 | 0.150 |
Why?
|
Phagosomes | 2 | 2014 | 39 | 0.150 |
Why?
|
Cerebral Cortex | 6 | 2005 | 584 | 0.150 |
Why?
|
Plaque, Atherosclerotic | 1 | 2018 | 54 | 0.150 |
Why?
|
Intellectual Disability | 2 | 2015 | 185 | 0.150 |
Why?
|
Green Fluorescent Proteins | 2 | 2015 | 305 | 0.150 |
Why?
|
Protein Multimerization | 2 | 2015 | 172 | 0.150 |
Why?
|
Brain Diseases | 1 | 2018 | 180 | 0.150 |
Why?
|
Dietary Proteins | 3 | 1996 | 30 | 0.150 |
Why?
|
Papillomaviridae | 2 | 1997 | 153 | 0.150 |
Why?
|
Prostate-Specific Antigen | 1 | 2019 | 346 | 0.150 |
Why?
|
Physostigmine | 3 | 1994 | 19 | 0.150 |
Why?
|
Receptors, LDL | 2 | 2014 | 53 | 0.150 |
Why?
|
Peroxisome Proliferator-Activated Receptors | 2 | 2006 | 8 | 0.150 |
Why?
|
Norepinephrine | 3 | 1994 | 167 | 0.150 |
Why?
|
Psychosurgery | 2 | 1995 | 13 | 0.150 |
Why?
|
Psychotropic Drugs | 1 | 1997 | 75 | 0.150 |
Why?
|
Suicide, Attempted | 2 | 2015 | 128 | 0.150 |
Why?
|
Narcotic Antagonists | 1 | 2018 | 153 | 0.140 |
Why?
|
Homozygote | 2 | 2014 | 200 | 0.140 |
Why?
|
Medication Therapy Management | 1 | 2016 | 16 | 0.140 |
Why?
|
Deinstitutionalization | 1 | 2016 | 2 | 0.140 |
Why?
|
DNA, Mitochondrial | 6 | 2001 | 183 | 0.140 |
Why?
|
Paternal Age | 2 | 2006 | 5 | 0.140 |
Why?
|
25-Hydroxyvitamin D 2 | 2 | 2014 | 5 | 0.140 |
Why?
|
Urban Population | 1 | 1997 | 213 | 0.140 |
Why?
|
Vitamin K 1 | 2 | 2014 | 4 | 0.140 |
Why?
|
Down-Regulation | 3 | 2019 | 503 | 0.140 |
Why?
|
Hepatitis Antibodies | 2 | 1995 | 6 | 0.140 |
Why?
|
Viral Hepatitis Vaccines | 2 | 1995 | 5 | 0.140 |
Why?
|
Patient Reported Outcome Measures | 1 | 2017 | 165 | 0.140 |
Why?
|
Calcifediol | 2 | 2014 | 21 | 0.140 |
Why?
|
Social Participation | 1 | 2016 | 14 | 0.140 |
Why?
|
Drug Approval | 2 | 2008 | 62 | 0.140 |
Why?
|
Cathartics | 1 | 1996 | 27 | 0.140 |
Why?
|
Cognitive Dysfunction | 1 | 2018 | 132 | 0.140 |
Why?
|
Radiosurgery | 1 | 2019 | 265 | 0.140 |
Why?
|
Chylomicron Remnants | 1 | 2015 | 2 | 0.140 |
Why?
|
Bone Density | 3 | 2002 | 209 | 0.140 |
Why?
|
Drug Resistance | 1 | 2016 | 256 | 0.140 |
Why?
|
Community Health Planning | 1 | 2015 | 21 | 0.140 |
Why?
|
Erlotinib Hydrochloride | 1 | 2015 | 90 | 0.140 |
Why?
|
Antineoplastic Agents, Immunological | 1 | 2018 | 185 | 0.140 |
Why?
|
rho-Associated Kinases | 2 | 2014 | 159 | 0.140 |
Why?
|
Employment | 1 | 2016 | 52 | 0.140 |
Why?
|
Brain | 8 | 1998 | 2208 | 0.140 |
Why?
|
Chemotaxis | 1 | 2016 | 72 | 0.140 |
Why?
|
Avena | 2 | 2007 | 17 | 0.140 |
Why?
|
Neutropenia | 3 | 2002 | 214 | 0.140 |
Why?
|
Immunological Synapses | 1 | 2015 | 5 | 0.140 |
Why?
|
Capecitabine | 1 | 2015 | 87 | 0.130 |
Why?
|
Microvessels | 1 | 2015 | 69 | 0.130 |
Why?
|
Immunosuppressive Agents | 2 | 2003 | 977 | 0.130 |
Why?
|
Patient Safety | 1 | 2018 | 210 | 0.130 |
Why?
|
Product Surveillance, Postmarketing | 2 | 2006 | 37 | 0.130 |
Why?
|
Receptors, Dopamine | 4 | 2001 | 38 | 0.130 |
Why?
|
Perfusion Imaging | 1 | 2015 | 50 | 0.130 |
Why?
|
Abdomen | 3 | 2009 | 121 | 0.130 |
Why?
|
Confidence Intervals | 3 | 2009 | 228 | 0.130 |
Why?
|
Anti-Anxiety Agents | 2 | 1994 | 22 | 0.130 |
Why?
|
Actin Cytoskeleton | 2 | 2014 | 190 | 0.130 |
Why?
|
Psychomotor Disorders | 1 | 2015 | 20 | 0.130 |
Why?
|
Ultrasonics | 1 | 2015 | 38 | 0.130 |
Why?
|
Diabetes Mellitus, Type 1 | 6 | 2010 | 565 | 0.130 |
Why?
|
Endocrinology | 1 | 2017 | 66 | 0.130 |
Why?
|
Actomyosin | 1 | 2015 | 45 | 0.130 |
Why?
|
beta Carotene | 1 | 2014 | 4 | 0.130 |
Why?
|
Spectrometry, Fluorescence | 1 | 2015 | 85 | 0.130 |
Why?
|
Microspheres | 1 | 2015 | 97 | 0.130 |
Why?
|
Prothrombin | 1 | 2014 | 18 | 0.130 |
Why?
|
beta-Alanine | 1 | 2014 | 6 | 0.130 |
Why?
|
alpha-Tocopherol | 1 | 2014 | 9 | 0.130 |
Why?
|
Cytoplasmic Granules | 1 | 2015 | 94 | 0.130 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 316 | 0.130 |
Why?
|
Curriculum | 2 | 2009 | 537 | 0.130 |
Why?
|
Coronavirus Infections | 1 | 2020 | 301 | 0.130 |
Why?
|
Vitamin A | 1 | 2014 | 27 | 0.130 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2018 | 453 | 0.130 |
Why?
|
Myocardial Revascularization | 3 | 2013 | 31 | 0.130 |
Why?
|
Genotype | 7 | 2020 | 1849 | 0.130 |
Why?
|
Receptors, Prostaglandin | 3 | 2009 | 7 | 0.130 |
Why?
|
Quantum Dots | 1 | 2014 | 19 | 0.130 |
Why?
|
Phospholipids | 5 | 2015 | 111 | 0.130 |
Why?
|
Immunization, Secondary | 1 | 1994 | 30 | 0.130 |
Why?
|
Immunologic Memory | 1 | 2016 | 152 | 0.130 |
Why?
|
Glycocalyx | 1 | 2014 | 2 | 0.130 |
Why?
|
Vasa Vasorum | 1 | 2014 | 4 | 0.130 |
Why?
|
Reoperation | 3 | 2014 | 588 | 0.130 |
Why?
|
Nerve Tissue Proteins | 2 | 2014 | 503 | 0.130 |
Why?
|
Tomography, X-Ray Computed | 5 | 2010 | 2592 | 0.130 |
Why?
|
Gene Transfer Techniques | 1 | 2015 | 152 | 0.130 |
Why?
|
Placebo Effect | 4 | 2016 | 31 | 0.130 |
Why?
|
Plasmids | 1 | 2015 | 287 | 0.130 |
Why?
|
Uterine Cervicitis | 1 | 1994 | 4 | 0.130 |
Why?
|
Disease-Free Survival | 5 | 2015 | 1203 | 0.120 |
Why?
|
Length of Stay | 5 | 2013 | 697 | 0.120 |
Why?
|
Antineoplastic Agents | 2 | 2015 | 2350 | 0.120 |
Why?
|
Postoperative Hemorrhage | 1 | 2014 | 44 | 0.120 |
Why?
|
src-Family Kinases | 1 | 2014 | 74 | 0.120 |
Why?
|
Cholinergic Fibers | 2 | 1991 | 23 | 0.120 |
Why?
|
Withholding Treatment | 2 | 2013 | 111 | 0.120 |
Why?
|
Receptors, AMPA | 1 | 2014 | 66 | 0.120 |
Why?
|
Overweight | 2 | 2013 | 118 | 0.120 |
Why?
|
p21-Activated Kinases | 1 | 2014 | 15 | 0.120 |
Why?
|
Myristic Acid | 1 | 2014 | 2 | 0.120 |
Why?
|
Cell Line, Tumor | 4 | 2014 | 2419 | 0.120 |
Why?
|
Protein Precursors | 1 | 2014 | 143 | 0.120 |
Why?
|
Jews | 2 | 2008 | 42 | 0.120 |
Why?
|
Uterine Cervical Dysplasia | 1 | 1994 | 27 | 0.120 |
Why?
|
Transcatheter Aortic Valve Replacement | 1 | 2014 | 47 | 0.120 |
Why?
|
Drug Evaluation, Preclinical | 1 | 2014 | 103 | 0.120 |
Why?
|
Executive Function | 1 | 2015 | 86 | 0.120 |
Why?
|
Lectins, C-Type | 1 | 2014 | 85 | 0.120 |
Why?
|
Weight Gain | 3 | 2005 | 123 | 0.120 |
Why?
|
Fatty Acid Desaturases | 1 | 2013 | 17 | 0.120 |
Why?
|
Amides | 2 | 2011 | 59 | 0.120 |
Why?
|
rhoA GTP-Binding Protein | 1 | 2014 | 83 | 0.120 |
Why?
|
Cell Shape | 1 | 2014 | 50 | 0.120 |
Why?
|
Motor Activity | 3 | 2005 | 327 | 0.120 |
Why?
|
Stress, Physiological | 1 | 2015 | 226 | 0.120 |
Why?
|
Low Back Pain | 1 | 2014 | 40 | 0.120 |
Why?
|
Depression | 2 | 1998 | 472 | 0.120 |
Why?
|
Receptors, Immunologic | 3 | 2009 | 135 | 0.120 |
Why?
|
Heart Failure | 3 | 2011 | 1193 | 0.120 |
Why?
|
Collagen | 1 | 2015 | 268 | 0.120 |
Why?
|
Absorption | 1 | 2013 | 25 | 0.120 |
Why?
|
Tumor Virus Infections | 1 | 1994 | 81 | 0.120 |
Why?
|
T-Lymphocytes, Cytotoxic | 1 | 2015 | 314 | 0.120 |
Why?
|
Clinical Competence | 2 | 2009 | 750 | 0.120 |
Why?
|
Fungi | 1 | 2014 | 65 | 0.120 |
Why?
|
Glycine | 1 | 2014 | 90 | 0.120 |
Why?
|
Cytochrome P-450 CYP3A | 2 | 2006 | 43 | 0.120 |
Why?
|
Myocardial Perfusion Imaging | 1 | 2013 | 47 | 0.120 |
Why?
|
Caspase 3 | 1 | 2014 | 159 | 0.120 |
Why?
|
Endpoint Determination | 1 | 2013 | 60 | 0.120 |
Why?
|
Bioprosthesis | 1 | 2013 | 36 | 0.120 |
Why?
|
Aortic Aneurysm, Thoracic | 1 | 2014 | 87 | 0.120 |
Why?
|
Purines | 1 | 2013 | 91 | 0.120 |
Why?
|
Clonidine | 2 | 1994 | 37 | 0.120 |
Why?
|
Vascular Surgical Procedures | 1 | 2014 | 148 | 0.120 |
Why?
|
Midazolam | 1 | 2013 | 48 | 0.120 |
Why?
|
Exercise | 3 | 2014 | 314 | 0.120 |
Why?
|
Dexmedetomidine | 1 | 2013 | 11 | 0.120 |
Why?
|
Peer Group | 2 | 2004 | 72 | 0.120 |
Why?
|
Receptors, Dopamine D2 | 1 | 1993 | 57 | 0.120 |
Why?
|
Vaccines, Inactivated | 2 | 1995 | 29 | 0.110 |
Why?
|
Mitochondria | 5 | 1996 | 535 | 0.110 |
Why?
|
Chemistry, Pharmaceutical | 1 | 2013 | 59 | 0.110 |
Why?
|
Chemical Precipitation | 1 | 2012 | 18 | 0.110 |
Why?
|
Microtubule-Associated Proteins | 1 | 2014 | 176 | 0.110 |
Why?
|
Ultracentrifugation | 1 | 2012 | 42 | 0.110 |
Why?
|
Heart Valve Prosthesis | 1 | 2013 | 93 | 0.110 |
Why?
|
Feces | 2 | 2013 | 316 | 0.110 |
Why?
|
Genomics | 1 | 2018 | 704 | 0.110 |
Why?
|
Muscle, Smooth, Vascular | 1 | 2014 | 231 | 0.110 |
Why?
|
Aortic Valve Stenosis | 1 | 2014 | 129 | 0.110 |
Why?
|
Protein Interaction Mapping | 1 | 2013 | 82 | 0.110 |
Why?
|
Conscious Sedation | 1 | 2013 | 64 | 0.110 |
Why?
|
Perphenazine | 1 | 2012 | 2 | 0.110 |
Why?
|
Proteolysis | 1 | 2013 | 100 | 0.110 |
Why?
|
Romania | 1 | 2012 | 4 | 0.110 |
Why?
|
Hypoglycemia | 2 | 2012 | 106 | 0.110 |
Why?
|
Ezetimibe, Simvastatin Drug Combination | 3 | 2009 | 3 | 0.110 |
Why?
|
Nervous System Diseases | 1 | 2014 | 151 | 0.110 |
Why?
|
Foam Cells | 2 | 2009 | 17 | 0.110 |
Why?
|
Dextran Sulfate | 1 | 2012 | 68 | 0.110 |
Why?
|
Gastrointestinal Diseases | 2 | 2013 | 145 | 0.110 |
Why?
|
Treatment Failure | 3 | 2010 | 284 | 0.110 |
Why?
|
Heart Valve Diseases | 1 | 2013 | 108 | 0.110 |
Why?
|
Pyrazoles | 1 | 2013 | 153 | 0.110 |
Why?
|
Lipoprotein Lipase | 2 | 2020 | 14 | 0.110 |
Why?
|
Child Development Disorders, Pervasive | 1 | 2012 | 39 | 0.110 |
Why?
|
Controlled Clinical Trials as Topic | 2 | 2011 | 24 | 0.110 |
Why?
|
Parietal Lobe | 1 | 1993 | 117 | 0.110 |
Why?
|
Arrhythmias, Cardiac | 2 | 2011 | 187 | 0.110 |
Why?
|
Magnetic Resonance Imaging, Cine | 1 | 2013 | 159 | 0.110 |
Why?
|
Filgrastim | 2 | 2002 | 56 | 0.110 |
Why?
|
Ventricular Function, Left | 4 | 2013 | 589 | 0.110 |
Why?
|
Aspartate Aminotransferases | 2 | 2010 | 73 | 0.110 |
Why?
|
Morbidity | 2 | 2010 | 145 | 0.110 |
Why?
|
Pharmacogenetics | 1 | 2016 | 434 | 0.110 |
Why?
|
Molecular Structure | 2 | 2012 | 287 | 0.110 |
Why?
|
Sweden | 3 | 2013 | 40 | 0.110 |
Why?
|
Health Status Indicators | 2 | 2009 | 105 | 0.110 |
Why?
|
Antisocial Personality Disorder | 1 | 2013 | 91 | 0.110 |
Why?
|
Hepatovirus | 1 | 1992 | 1 | 0.110 |
Why?
|
Cost-Benefit Analysis | 7 | 2017 | 450 | 0.110 |
Why?
|
Clinical Trials, Phase I as Topic | 1 | 2013 | 149 | 0.110 |
Why?
|
HeLa Cells | 5 | 2014 | 498 | 0.110 |
Why?
|
Hypnotics and Sedatives | 1 | 2013 | 124 | 0.110 |
Why?
|
Mitral Valve Insufficiency | 2 | 2014 | 187 | 0.110 |
Why?
|
Reference Standards | 1 | 2012 | 159 | 0.110 |
Why?
|
Causality | 2 | 2007 | 81 | 0.110 |
Why?
|
Osteoporosis, Postmenopausal | 2 | 2002 | 34 | 0.110 |
Why?
|
Photochemical Processes | 1 | 2011 | 14 | 0.110 |
Why?
|
Serine | 1 | 2012 | 98 | 0.110 |
Why?
|
Verbal Learning | 4 | 2013 | 30 | 0.100 |
Why?
|
Medication Adherence | 1 | 2013 | 129 | 0.100 |
Why?
|
Hyperlipoproteinemias | 1 | 1991 | 7 | 0.100 |
Why?
|
Behavior | 2 | 1994 | 85 | 0.100 |
Why?
|
Liraglutide | 1 | 2011 | 5 | 0.100 |
Why?
|
RNA, Messenger | 3 | 2015 | 1974 | 0.100 |
Why?
|
Mice | 9 | 2015 | 11279 | 0.100 |
Why?
|
Antibodies, Viral | 1 | 2013 | 292 | 0.100 |
Why?
|
Neoplasm Staging | 5 | 2015 | 1932 | 0.100 |
Why?
|
Venoms | 1 | 2011 | 12 | 0.100 |
Why?
|
Ischemic Preconditioning, Myocardial | 1 | 2011 | 12 | 0.100 |
Why?
|
Alendronate | 2 | 2002 | 12 | 0.100 |
Why?
|
Apolipoprotein E4 | 3 | 2020 | 27 | 0.100 |
Why?
|
Gastric Emptying | 1 | 2011 | 23 | 0.100 |
Why?
|
Substance-Related Disorders | 2 | 2013 | 388 | 0.100 |
Why?
|
Mitral Valve | 1 | 2013 | 247 | 0.100 |
Why?
|
Protein Processing, Post-Translational | 1 | 2014 | 368 | 0.100 |
Why?
|
Meta-Analysis as Topic | 1 | 2011 | 88 | 0.100 |
Why?
|
Motor Cortex | 1 | 1993 | 195 | 0.100 |
Why?
|
Calcium | 2 | 2007 | 1147 | 0.100 |
Why?
|
Epithelial Cells | 1 | 2015 | 662 | 0.100 |
Why?
|
Intracellular Signaling Peptides and Proteins | 2 | 2014 | 377 | 0.100 |
Why?
|
Sitosterols | 1 | 2011 | 3 | 0.100 |
Why?
|
Hydrocortisone | 5 | 2000 | 298 | 0.100 |
Why?
|
Cause of Death | 3 | 2004 | 277 | 0.100 |
Why?
|
Endothelial Cells | 1 | 2014 | 424 | 0.100 |
Why?
|
Quinazolinones | 1 | 2011 | 13 | 0.100 |
Why?
|
Up-Regulation | 2 | 2015 | 710 | 0.100 |
Why?
|
Receptors, CCR2 | 1 | 2011 | 35 | 0.100 |
Why?
|
Diet, High-Fat | 1 | 2012 | 111 | 0.100 |
Why?
|
Chemokine CCL2 | 1 | 2011 | 47 | 0.100 |
Why?
|
Papillomavirus Infections | 1 | 1994 | 239 | 0.100 |
Why?
|
Steroid 11-beta-Hydroxylase | 1 | 2010 | 1 | 0.100 |
Why?
|
Macrophages | 1 | 2014 | 553 | 0.100 |
Why?
|
Child, Preschool | 5 | 2012 | 3608 | 0.100 |
Why?
|
Substance Withdrawal Syndrome | 1 | 1991 | 48 | 0.100 |
Why?
|
Receptors, Cholinergic | 1 | 1991 | 76 | 0.100 |
Why?
|
Energy Intake | 2 | 2002 | 97 | 0.100 |
Why?
|
Health Personnel | 2 | 1995 | 201 | 0.100 |
Why?
|
RNA, Transfer, Leu | 4 | 1995 | 11 | 0.090 |
Why?
|
Psychomotor Agitation | 2 | 2005 | 26 | 0.090 |
Why?
|
Methylcellulose | 2 | 2000 | 6 | 0.090 |
Why?
|
Biomarkers, Tumor | 1 | 2018 | 1459 | 0.090 |
Why?
|
Long-Term Care | 2 | 2001 | 60 | 0.090 |
Why?
|
Discriminant Analysis | 2 | 2002 | 66 | 0.090 |
Why?
|
Self Care | 4 | 2019 | 164 | 0.090 |
Why?
|
Recombinant Proteins | 2 | 2002 | 1014 | 0.090 |
Why?
|
Therapeutic Equivalency | 2 | 2008 | 12 | 0.090 |
Why?
|
Insurance Claim Review | 1 | 2010 | 41 | 0.090 |
Why?
|
Polyphenols | 1 | 2009 | 13 | 0.090 |
Why?
|
Scavenger Receptors, Class A | 1 | 2009 | 5 | 0.090 |
Why?
|
Multicenter Studies as Topic | 4 | 2014 | 152 | 0.090 |
Why?
|
Liver X Receptors | 1 | 2009 | 12 | 0.090 |
Why?
|
Orphan Nuclear Receptors | 1 | 2009 | 13 | 0.090 |
Why?
|
Phenols | 1 | 2009 | 40 | 0.090 |
Why?
|
Waist Circumference | 1 | 2009 | 20 | 0.090 |
Why?
|
Receptors, Serotonin | 3 | 1994 | 34 | 0.090 |
Why?
|
Fat Emulsions, Intravenous | 1 | 2009 | 13 | 0.090 |
Why?
|
CD36 Antigens | 1 | 2009 | 13 | 0.090 |
Why?
|
Chi-Square Distribution | 1 | 2010 | 362 | 0.090 |
Why?
|
Folic Acid | 1 | 2009 | 60 | 0.090 |
Why?
|
Membrane Proteins | 3 | 2010 | 1194 | 0.090 |
Why?
|
Neurons | 3 | 2014 | 1545 | 0.090 |
Why?
|
Peripheral Nervous System Diseases | 3 | 2006 | 85 | 0.090 |
Why?
|
Canada | 3 | 2008 | 203 | 0.090 |
Why?
|
Administration, Cutaneous | 2 | 1999 | 58 | 0.090 |
Why?
|
Health Maintenance Organizations | 1 | 2009 | 20 | 0.090 |
Why?
|
Flavonoids | 1 | 2009 | 85 | 0.090 |
Why?
|
Suture Techniques | 1 | 2010 | 134 | 0.090 |
Why?
|
Factor Analysis, Statistical | 4 | 2015 | 111 | 0.080 |
Why?
|
Dementia, Vascular | 2 | 2005 | 7 | 0.080 |
Why?
|
Synaptic Transmission | 1 | 2010 | 222 | 0.080 |
Why?
|
Computers, Handheld | 1 | 2009 | 32 | 0.080 |
Why?
|
Diarrhea | 3 | 2005 | 181 | 0.080 |
Why?
|
Liver Failure | 2 | 2006 | 78 | 0.080 |
Why?
|
Single-Blind Method | 3 | 2002 | 151 | 0.080 |
Why?
|
Judaism | 1 | 2008 | 5 | 0.080 |
Why?
|
Intermittent Claudication | 2 | 1998 | 20 | 0.080 |
Why?
|
Hippocampus | 3 | 2005 | 442 | 0.080 |
Why?
|
Cytochrome b Group | 1 | 1988 | 10 | 0.080 |
Why?
|
Microfilament Proteins | 1 | 2010 | 206 | 0.080 |
Why?
|
Bacillus | 1 | 1988 | 12 | 0.080 |
Why?
|
Age Distribution | 2 | 2007 | 204 | 0.080 |
Why?
|
Drosophila melanogaster | 1 | 2013 | 595 | 0.080 |
Why?
|
Cell Line | 6 | 2015 | 2462 | 0.080 |
Why?
|
Renal Insufficiency | 2 | 2006 | 114 | 0.080 |
Why?
|
Subcutaneous Fat | 1 | 2008 | 18 | 0.080 |
Why?
|
Microscopy, Confocal | 3 | 2015 | 268 | 0.080 |
Why?
|
Cytochrome c Group | 1 | 1988 | 82 | 0.080 |
Why?
|
Drug Design | 1 | 2008 | 124 | 0.080 |
Why?
|
Particle Size | 2 | 2006 | 121 | 0.080 |
Why?
|
Ischemic Attack, Transient | 1 | 2010 | 181 | 0.080 |
Why?
|
Antioxidants | 1 | 2009 | 223 | 0.080 |
Why?
|
Liver Diseases | 2 | 2006 | 238 | 0.080 |
Why?
|
Tetrazoles | 2 | 1998 | 50 | 0.080 |
Why?
|
Medroxyprogesterone Acetate | 3 | 2002 | 21 | 0.080 |
Why?
|
Dyslexia | 1 | 2007 | 11 | 0.080 |
Why?
|
Monocytes | 1 | 2009 | 214 | 0.080 |
Why?
|
Magnetic Resonance Imaging | 2 | 2015 | 3338 | 0.080 |
Why?
|
Personality Disorders | 3 | 2001 | 146 | 0.080 |
Why?
|
Triticum | 1 | 2007 | 32 | 0.080 |
Why?
|
Protein Binding | 4 | 2015 | 1451 | 0.080 |
Why?
|
Paliperidone Palmitate | 1 | 2007 | 2 | 0.080 |
Why?
|
Chicago | 2 | 2009 | 1377 | 0.080 |
Why?
|
Hormones | 1 | 1988 | 140 | 0.080 |
Why?
|
New York | 2 | 1997 | 69 | 0.080 |
Why?
|
Blood Pressure Monitoring, Ambulatory | 1 | 2008 | 83 | 0.080 |
Why?
|
Cat Diseases | 1 | 2007 | 20 | 0.080 |
Why?
|
Probability | 3 | 2010 | 355 | 0.080 |
Why?
|
Coffee | 1 | 2007 | 10 | 0.080 |
Why?
|
Acute Disease | 3 | 2006 | 824 | 0.080 |
Why?
|
Dog Diseases | 1 | 2007 | 35 | 0.080 |
Why?
|
Socioeconomic Factors | 3 | 2005 | 567 | 0.080 |
Why?
|
Comprehension | 1 | 2007 | 79 | 0.080 |
Why?
|
Platelet Aggregation Inhibitors | 2 | 1998 | 132 | 0.080 |
Why?
|
Point Mutation | 4 | 2013 | 246 | 0.080 |
Why?
|
Cytochrome P-450 CYP3A Inhibitors | 1 | 2006 | 5 | 0.070 |
Why?
|
Neurologic Examination | 1 | 2007 | 118 | 0.070 |
Why?
|
Residence Characteristics | 3 | 2012 | 195 | 0.070 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 2015 | 1073 | 0.070 |
Why?
|
Dibenzothiazepines | 1 | 2006 | 4 | 0.070 |
Why?
|
Myocardial Infarction | 5 | 2013 | 372 | 0.070 |
Why?
|
Statistics, Nonparametric | 2 | 2011 | 307 | 0.070 |
Why?
|
Religion and Medicine | 1 | 2008 | 121 | 0.070 |
Why?
|
Nausea | 2 | 2005 | 175 | 0.070 |
Why?
|
Sterol Regulatory Element Binding Protein 1 | 1 | 2006 | 12 | 0.070 |
Why?
|
Attention | 5 | 1995 | 386 | 0.070 |
Why?
|
Rats | 5 | 2014 | 3982 | 0.070 |
Why?
|
Biotransformation | 1 | 2006 | 50 | 0.070 |
Why?
|
Hepatocyte Nuclear Factor 4 | 1 | 2006 | 30 | 0.070 |
Why?
|
Lipogenesis | 1 | 2006 | 22 | 0.070 |
Why?
|
Mitral Valve Prolapse | 1 | 1986 | 22 | 0.070 |
Why?
|
Glucose Tolerance Test | 1 | 2007 | 228 | 0.070 |
Why?
|
Cytochrome P-450 Enzyme Inhibitors | 1 | 2006 | 10 | 0.070 |
Why?
|
Sexual Behavior | 2 | 2002 | 300 | 0.070 |
Why?
|
Body Temperature | 4 | 1999 | 124 | 0.070 |
Why?
|
Blood Proteins | 2 | 2003 | 144 | 0.070 |
Why?
|
Guidelines as Topic | 1 | 2007 | 162 | 0.070 |
Why?
|
Postoperative Complications | 2 | 2013 | 2182 | 0.070 |
Why?
|
Managed Care Programs | 1 | 2006 | 42 | 0.070 |
Why?
|
Immunoglobulin G | 3 | 2013 | 455 | 0.070 |
Why?
|
Administration, Inhalation | 1 | 2006 | 188 | 0.070 |
Why?
|
HIV-Associated Lipodystrophy Syndrome | 1 | 2005 | 2 | 0.070 |
Why?
|
Agranulocytosis | 1 | 1985 | 20 | 0.070 |
Why?
|
Raloxifene Hydrochloride | 1 | 2005 | 9 | 0.070 |
Why?
|
Polymerase Chain Reaction | 3 | 1998 | 927 | 0.070 |
Why?
|
Adaptor Proteins, Vesicular Transport | 2 | 2014 | 49 | 0.070 |
Why?
|
Creatinine | 1 | 2006 | 337 | 0.070 |
Why?
|
Capsules | 1 | 2005 | 38 | 0.070 |
Why?
|
Anti-Inflammatory Agents | 1 | 2008 | 337 | 0.070 |
Why?
|
Epidemiologic Research Design | 1 | 2005 | 22 | 0.070 |
Why?
|
Body Size | 1 | 2006 | 91 | 0.070 |
Why?
|
Autistic Disorder | 1 | 2006 | 147 | 0.070 |
Why?
|
Polymorphism, Single Nucleotide | 2 | 2011 | 2347 | 0.070 |
Why?
|
Kaplan-Meier Estimate | 3 | 2013 | 859 | 0.070 |
Why?
|
Colestipol | 2 | 1995 | 3 | 0.070 |
Why?
|
Ambulatory Care | 2 | 2017 | 180 | 0.070 |
Why?
|
Spermatozoa | 1 | 2005 | 61 | 0.070 |
Why?
|
Serotonin | 4 | 1994 | 218 | 0.070 |
Why?
|
Viscosity | 3 | 2000 | 46 | 0.070 |
Why?
|
Creatine Kinase, MM Form | 1 | 2004 | 1 | 0.070 |
Why?
|
Muscles | 1 | 1985 | 192 | 0.060 |
Why?
|
DNA, Viral | 2 | 1997 | 265 | 0.060 |
Why?
|
Inpatients | 3 | 2016 | 295 | 0.060 |
Why?
|
Heart | 3 | 1998 | 538 | 0.060 |
Why?
|
Carotenoids | 2 | 2001 | 14 | 0.060 |
Why?
|
Peptide Fragments | 1 | 2006 | 459 | 0.060 |
Why?
|
Tomography, Emission-Computed | 3 | 1994 | 103 | 0.060 |
Why?
|
Hyponatremia | 1 | 2004 | 25 | 0.060 |
Why?
|
Body Height | 1 | 2005 | 99 | 0.060 |
Why?
|
Home Care Services | 2 | 2003 | 72 | 0.060 |
Why?
|
Biological Transport, Active | 1 | 2004 | 101 | 0.060 |
Why?
|
Contrast Media | 2 | 2013 | 1076 | 0.060 |
Why?
|
Physical Conditioning, Animal | 1 | 2004 | 19 | 0.060 |
Why?
|
ATP Citrate (pro-S)-Lyase | 2 | 2014 | 3 | 0.060 |
Why?
|
MELAS Syndrome | 2 | 1995 | 3 | 0.060 |
Why?
|
Mannose-Binding Lectin | 1 | 2004 | 3 | 0.060 |
Why?
|
Pseudopodia | 2 | 2015 | 35 | 0.060 |
Why?
|
Europe | 3 | 2013 | 308 | 0.060 |
Why?
|
Eating | 1 | 2005 | 166 | 0.060 |
Why?
|
Fatty Liver | 1 | 2005 | 124 | 0.060 |
Why?
|
Kidney Tubules | 1 | 2004 | 94 | 0.060 |
Why?
|
Health Knowledge, Attitudes, Practice | 2 | 2011 | 508 | 0.060 |
Why?
|
Hormone Replacement Therapy | 2 | 2002 | 77 | 0.060 |
Why?
|
Gout Suppressants | 1 | 2004 | 36 | 0.060 |
Why?
|
Bulbar Palsy, Progressive | 1 | 2003 | 1 | 0.060 |
Why?
|
Serotonin Receptor Agonists | 2 | 1994 | 15 | 0.060 |
Why?
|
Molecular Sequence Data | 5 | 2015 | 3027 | 0.060 |
Why?
|
Liver Function Tests | 2 | 2002 | 93 | 0.060 |
Why?
|
Substrate Specificity | 1 | 2004 | 347 | 0.060 |
Why?
|
Physical Examination | 1 | 2004 | 148 | 0.060 |
Why?
|
Pressure | 2 | 2014 | 162 | 0.060 |
Why?
|
Fluorocarbons | 1 | 2004 | 72 | 0.060 |
Why?
|
Dose-Response Relationship, Immunologic | 1 | 2003 | 42 | 0.060 |
Why?
|
AMP-Activated Protein Kinases | 2 | 2014 | 64 | 0.060 |
Why?
|
Phosphorylation | 3 | 2014 | 1101 | 0.060 |
Why?
|
Microscopy, Fluorescence | 2 | 2015 | 424 | 0.060 |
Why?
|
Amino Acid Sequence | 4 | 2015 | 2061 | 0.060 |
Why?
|
Albumins | 1 | 2004 | 133 | 0.060 |
Why?
|
Prolactin | 5 | 1994 | 88 | 0.060 |
Why?
|
Security Measures | 1 | 2003 | 2 | 0.060 |
Why?
|
Commitment of Mentally Ill | 1 | 2003 | 2 | 0.060 |
Why?
|
Molecular Weight | 3 | 2011 | 332 | 0.060 |
Why?
|
Galantamine | 1 | 2003 | 1 | 0.060 |
Why?
|
Telephone | 1 | 2003 | 32 | 0.060 |
Why?
|
Lung Neoplasms | 1 | 2015 | 2258 | 0.060 |
Why?
|
Social Alienation | 1 | 2002 | 1 | 0.060 |
Why?
|
Alcoholism | 3 | 1993 | 170 | 0.060 |
Why?
|
Clostridium Infections | 1 | 1985 | 125 | 0.060 |
Why?
|
Diglycerides | 1 | 2002 | 22 | 0.060 |
Why?
|
Apolipoproteins C | 1 | 2002 | 5 | 0.060 |
Why?
|
Gastrostomy | 1 | 2003 | 69 | 0.060 |
Why?
|
Sex Distribution | 2 | 2018 | 173 | 0.060 |
Why?
|
Specialty Boards | 1 | 2003 | 24 | 0.060 |
Why?
|
Mood Disorders | 2 | 2001 | 80 | 0.060 |
Why?
|
Diet, Reducing | 1 | 2002 | 31 | 0.060 |
Why?
|
Hospital Units | 1 | 2003 | 30 | 0.060 |
Why?
|
HEK293 Cells | 2 | 2015 | 615 | 0.060 |
Why?
|
Drug Synergism | 1 | 2003 | 303 | 0.060 |
Why?
|
Health Services for the Aged | 1 | 2003 | 27 | 0.060 |
Why?
|
Language Tests | 1 | 2002 | 37 | 0.060 |
Why?
|
Achievement | 1 | 2002 | 29 | 0.060 |
Why?
|
Metabolic Clearance Rate | 1 | 2002 | 121 | 0.060 |
Why?
|
Protein Transport | 2 | 2015 | 410 | 0.060 |
Why?
|
Interview, Psychological | 1 | 2002 | 69 | 0.060 |
Why?
|
Cell Survival | 3 | 2014 | 966 | 0.060 |
Why?
|
Brain Diseases, Metabolic | 2 | 1992 | 9 | 0.050 |
Why?
|
Serotyping | 3 | 2000 | 28 | 0.050 |
Why?
|
Testosterone | 2 | 2000 | 268 | 0.050 |
Why?
|
COS Cells | 2 | 2014 | 166 | 0.050 |
Why?
|
Neoplasm Metastasis | 2 | 2018 | 1056 | 0.050 |
Why?
|
Infant, Newborn | 4 | 1998 | 2367 | 0.050 |
Why?
|
Progestins | 1 | 2002 | 22 | 0.050 |
Why?
|
Illinois | 1 | 2003 | 461 | 0.050 |
Why?
|
Uterine Hemorrhage | 1 | 2002 | 19 | 0.050 |
Why?
|
Psychiatry | 1 | 2003 | 77 | 0.050 |
Why?
|
Neurotic Disorders | 1 | 2001 | 13 | 0.050 |
Why?
|
Viral Load | 1 | 2002 | 148 | 0.050 |
Why?
|
Amyotrophic Lateral Sclerosis | 1 | 2003 | 182 | 0.050 |
Why?
|
Hypothermia | 1 | 1981 | 26 | 0.050 |
Why?
|
Esterification | 1 | 2001 | 6 | 0.050 |
Why?
|
Hospitals, Community | 1 | 1981 | 31 | 0.050 |
Why?
|
Margarine | 1 | 2001 | 1 | 0.050 |
Why?
|
Sulfonic Acids | 1 | 2001 | 9 | 0.050 |
Why?
|
Hemodynamics | 3 | 2013 | 710 | 0.050 |
Why?
|
Etidronic Acid | 1 | 2001 | 5 | 0.050 |
Why?
|
Myocytes, Cardiac | 1 | 2004 | 275 | 0.050 |
Why?
|
Acetates | 1 | 2001 | 66 | 0.050 |
Why?
|
Cells, Cultured | 3 | 2015 | 2802 | 0.050 |
Why?
|
Somatostatin | 3 | 1996 | 55 | 0.050 |
Why?
|
Immunoglobulin A | 2 | 1998 | 79 | 0.050 |
Why?
|
Sickness Impact Profile | 1 | 2001 | 27 | 0.050 |
Why?
|
Immunoglobulin M | 2 | 1998 | 154 | 0.050 |
Why?
|
Haemophilus influenzae | 2 | 2000 | 13 | 0.050 |
Why?
|
Receptors, Histamine | 1 | 2001 | 5 | 0.050 |
Why?
|
Motor Neuron Disease | 1 | 2001 | 21 | 0.050 |
Why?
|
Basal Ganglia Diseases | 1 | 2001 | 9 | 0.050 |
Why?
|
Arousal | 2 | 1992 | 170 | 0.050 |
Why?
|
Mitochondria, Heart | 1 | 2001 | 50 | 0.050 |
Why?
|
Autopsy | 2 | 1998 | 116 | 0.050 |
Why?
|
Dogs | 2 | 2015 | 684 | 0.050 |
Why?
|
Receptors, Muscarinic | 1 | 2001 | 49 | 0.050 |
Why?
|
Androsterone | 1 | 2000 | 5 | 0.050 |
Why?
|
Contraindications | 1 | 2001 | 71 | 0.050 |
Why?
|
Blood Coagulation Factors | 1 | 2000 | 20 | 0.050 |
Why?
|
Neurofibrillary Tangles | 5 | 2005 | 45 | 0.050 |
Why?
|
Dihydrotestosterone | 1 | 2000 | 26 | 0.050 |
Why?
|
Adrenal Cortex | 1 | 2000 | 21 | 0.050 |
Why?
|
Naphthalenes | 1 | 2001 | 45 | 0.050 |
Why?
|
Diagnosis, Differential | 4 | 2003 | 1562 | 0.050 |
Why?
|
Haemophilus Vaccines | 1 | 2000 | 5 | 0.050 |
Why?
|
Infant | 6 | 2012 | 3037 | 0.050 |
Why?
|
Haemophilus Infections | 1 | 2000 | 6 | 0.050 |
Why?
|
Nutritional Status | 2 | 1999 | 83 | 0.050 |
Why?
|
Infant Nutritional Physiological Phenomena | 2 | 1970 | 19 | 0.050 |
Why?
|
Disease Models, Animal | 2 | 2020 | 2225 | 0.050 |
Why?
|
Immunization Programs | 1 | 2000 | 23 | 0.050 |
Why?
|
C-Peptide | 1 | 2000 | 174 | 0.050 |
Why?
|
Blood Component Removal | 1 | 2020 | 24 | 0.050 |
Why?
|
Acetylation | 1 | 2000 | 121 | 0.050 |
Why?
|
Acute-Phase Proteins | 1 | 2020 | 37 | 0.050 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2002 | 459 | 0.050 |
Why?
|
Telemedicine | 1 | 2003 | 165 | 0.050 |
Why?
|
Bacterial Infections | 1 | 2002 | 181 | 0.050 |
Why?
|
Congresses as Topic | 1 | 2001 | 116 | 0.050 |
Why?
|
Mice, Inbred C57BL | 2 | 2020 | 3077 | 0.050 |
Why?
|
Lipolysis | 1 | 2020 | 22 | 0.050 |
Why?
|
Fibrinogen | 1 | 2000 | 56 | 0.050 |
Why?
|
Psychomotor Performance | 2 | 1995 | 492 | 0.050 |
Why?
|
Endoscopy | 1 | 2003 | 331 | 0.050 |
Why?
|
ErbB Receptors | 2 | 2015 | 485 | 0.050 |
Why?
|
Affect | 1 | 2002 | 384 | 0.050 |
Why?
|
Aggression | 2 | 2019 | 320 | 0.050 |
Why?
|
Transdermal Patch | 1 | 2019 | 3 | 0.050 |
Why?
|
Neurites | 2 | 2013 | 35 | 0.050 |
Why?
|
Testis | 1 | 2000 | 152 | 0.050 |
Why?
|
Behavior Therapy | 1 | 2000 | 75 | 0.050 |
Why?
|
Milk | 1 | 1980 | 53 | 0.050 |
Why?
|
Whole-Body Irradiation | 1 | 1999 | 63 | 0.050 |
Why?
|
Lactose | 1 | 1999 | 27 | 0.050 |
Why?
|
Poultry | 1 | 1999 | 22 | 0.040 |
Why?
|
Endocarditis, Bacterial | 2 | 1992 | 33 | 0.040 |
Why?
|
Seafood | 1 | 1999 | 10 | 0.040 |
Why?
|
Knee Injuries | 1 | 2000 | 53 | 0.040 |
Why?
|
Cyclooxygenase Inhibitors | 1 | 1999 | 40 | 0.040 |
Why?
|
Prostaglandin-Endoperoxide Synthases | 1 | 1999 | 37 | 0.040 |
Why?
|
Infant, Premature | 2 | 1980 | 287 | 0.040 |
Why?
|
Steroids | 1 | 2000 | 172 | 0.040 |
Why?
|
Carbon Monoxide | 1 | 1999 | 88 | 0.040 |
Why?
|
Signal Transduction | 3 | 2014 | 3226 | 0.040 |
Why?
|
Motivation | 1 | 2002 | 286 | 0.040 |
Why?
|
Neoplasms | 1 | 2014 | 2881 | 0.040 |
Why?
|
Gum Arabic | 1 | 1998 | 1 | 0.040 |
Why?
|
Pectins | 1 | 1998 | 5 | 0.040 |
Why?
|
Gene Expression | 2 | 2013 | 1279 | 0.040 |
Why?
|
Cell Membrane | 2 | 2015 | 664 | 0.040 |
Why?
|
Thyroxine | 1 | 2000 | 344 | 0.040 |
Why?
|
Mitochondrial Myopathies | 1 | 1998 | 2 | 0.040 |
Why?
|
Schizotypal Personality Disorder | 2 | 1995 | 6 | 0.040 |
Why?
|
Violence | 1 | 2001 | 143 | 0.040 |
Why?
|
International Cooperation | 2 | 2009 | 126 | 0.040 |
Why?
|
Health Status | 1 | 2001 | 360 | 0.040 |
Why?
|
Decision Trees | 2 | 2013 | 63 | 0.040 |
Why?
|
RNA | 2 | 1993 | 559 | 0.040 |
Why?
|
Neuromuscular Diseases | 1 | 1998 | 30 | 0.040 |
Why?
|
Fever | 1 | 1999 | 125 | 0.040 |
Why?
|
Psychology, Adolescent | 1 | 1998 | 29 | 0.040 |
Why?
|
Primates | 1 | 2020 | 151 | 0.040 |
Why?
|
Seroepidemiologic Studies | 2 | 2013 | 54 | 0.040 |
Why?
|
Adrenocorticotropic Hormone | 5 | 2000 | 131 | 0.040 |
Why?
|
United Kingdom | 1 | 2018 | 164 | 0.040 |
Why?
|
Solubility | 1 | 1998 | 177 | 0.040 |
Why?
|
Coronary Circulation | 2 | 2015 | 127 | 0.040 |
Why?
|
Interpersonal Relations | 1 | 2019 | 170 | 0.040 |
Why?
|
London | 1 | 1997 | 16 | 0.040 |
Why?
|
Kidney Transplantation | 1 | 2005 | 846 | 0.040 |
Why?
|
Software | 1 | 2002 | 650 | 0.040 |
Why?
|
Pedigree | 2 | 2013 | 965 | 0.040 |
Why?
|
Molecular Dynamics Simulation | 1 | 2020 | 244 | 0.040 |
Why?
|
Anthropometry | 1 | 1997 | 74 | 0.040 |
Why?
|
Vitamin E | 1 | 1997 | 35 | 0.040 |
Why?
|
Emergency Service, Hospital | 1 | 1981 | 482 | 0.040 |
Why?
|
Peripheral Vascular Diseases | 1 | 1998 | 62 | 0.040 |
Why?
|
Gene Expression Regulation | 1 | 2006 | 1903 | 0.040 |
Why?
|
Platelet Function Tests | 1 | 2017 | 11 | 0.040 |
Why?
|
Physical Exertion | 2 | 2004 | 39 | 0.040 |
Why?
|
Feeding Behavior | 1 | 2000 | 324 | 0.040 |
Why?
|
Psychological Tests | 1 | 1997 | 91 | 0.040 |
Why?
|
Synaptic Vesicles | 1 | 1997 | 32 | 0.040 |
Why?
|
Quantitative Trait, Heritable | 1 | 2018 | 124 | 0.040 |
Why?
|
Amyloid beta-Protein Precursor | 1 | 1998 | 143 | 0.040 |
Why?
|
src Homology Domains | 1 | 1997 | 44 | 0.040 |
Why?
|
Diagnostic Techniques, Endocrine | 1 | 2017 | 7 | 0.040 |
Why?
|
Sucrose | 1 | 1997 | 63 | 0.040 |
Why?
|
Gyrus Cinguli | 1 | 1997 | 45 | 0.040 |
Why?
|
Temporal Lobe | 2 | 1996 | 172 | 0.040 |
Why?
|
Brief Psychiatric Rating Scale | 1 | 2016 | 6 | 0.040 |
Why?
|
Betacoronavirus | 1 | 2020 | 258 | 0.040 |
Why?
|
Global Health | 1 | 2018 | 193 | 0.040 |
Why?
|
Hydroxyindoleacetic Acid | 2 | 1994 | 27 | 0.040 |
Why?
|
Drug Tolerance | 1 | 1997 | 63 | 0.040 |
Why?
|
Reading | 1 | 1997 | 30 | 0.040 |
Why?
|
Carrier State | 1 | 1996 | 39 | 0.040 |
Why?
|
Rhodamines | 1 | 1996 | 18 | 0.040 |
Why?
|
Nursing Homes | 3 | 2005 | 109 | 0.040 |
Why?
|
Health Policy | 1 | 1998 | 180 | 0.040 |
Why?
|
Electron Transport | 1 | 1996 | 71 | 0.040 |
Why?
|
Cadherins | 1 | 1997 | 151 | 0.040 |
Why?
|
Blotting, Northern | 2 | 1993 | 256 | 0.040 |
Why?
|
Coloring Agents | 1 | 1996 | 64 | 0.040 |
Why?
|
HL-60 Cells | 1 | 2016 | 20 | 0.040 |
Why?
|
Immunohistochemistry | 2 | 1998 | 1752 | 0.040 |
Why?
|
Hepatitis A Vaccines | 2 | 1995 | 3 | 0.040 |
Why?
|
Hepatitis A Antibodies | 2 | 1995 | 3 | 0.040 |
Why?
|
Maternal Age | 2 | 2006 | 44 | 0.030 |
Why?
|
Immunization Schedule | 2 | 1995 | 21 | 0.030 |
Why?
|
Biomedical Research | 1 | 2020 | 375 | 0.030 |
Why?
|
Recurrence | 2 | 2010 | 1136 | 0.030 |
Why?
|
Madin Darby Canine Kidney Cells | 1 | 2015 | 17 | 0.030 |
Why?
|
Polymorphism, Genetic | 1 | 2000 | 819 | 0.030 |
Why?
|
Polymerization | 1 | 2015 | 32 | 0.030 |
Why?
|
Multiple Myeloma | 1 | 1999 | 307 | 0.030 |
Why?
|
Twins | 1 | 2015 | 65 | 0.030 |
Why?
|
Echocardiography | 2 | 2014 | 911 | 0.030 |
Why?
|
Cloning, Molecular | 2 | 2013 | 646 | 0.030 |
Why?
|
Binding, Competitive | 1 | 2015 | 145 | 0.030 |
Why?
|
Potoroidae | 1 | 2015 | 4 | 0.030 |
Why?
|
Neuropeptides | 1 | 1996 | 112 | 0.030 |
Why?
|
Schools | 1 | 2016 | 66 | 0.030 |
Why?
|
Siblings | 1 | 2016 | 111 | 0.030 |
Why?
|
Hepatitis A Virus, Human | 1 | 1995 | 1 | 0.030 |
Why?
|
Microscopy, Fluorescence, Multiphoton | 1 | 2015 | 14 | 0.030 |
Why?
|
Insulin Coma | 1 | 1995 | 1 | 0.030 |
Why?
|
Salvage Therapy | 1 | 1996 | 232 | 0.030 |
Why?
|
Germ-Line Mutation | 1 | 1998 | 324 | 0.030 |
Why?
|
Adaptor Proteins, Signal Transducing | 1 | 1997 | 302 | 0.030 |
Why?
|
Serial Learning | 1 | 1995 | 6 | 0.030 |
Why?
|
Electrophoresis, Polyacrylamide Gel | 3 | 1993 | 268 | 0.030 |
Why?
|
Suicidal Ideation | 1 | 2015 | 67 | 0.030 |
Why?
|
Antithrombins | 1 | 2014 | 12 | 0.030 |
Why?
|
Hemostatic Techniques | 1 | 2014 | 14 | 0.030 |
Why?
|
Injections, Intravenous | 1 | 2015 | 243 | 0.030 |
Why?
|
Heart Valve Prolapse | 1 | 2014 | 1 | 0.030 |
Why?
|
Models, Immunological | 1 | 2015 | 80 | 0.030 |
Why?
|
Vitamin D | 1 | 1997 | 261 | 0.030 |
Why?
|
Dabigatran | 1 | 2014 | 24 | 0.030 |
Why?
|
Matched-Pair Analysis | 1 | 1994 | 43 | 0.030 |
Why?
|
Genome, Human | 2 | 2013 | 755 | 0.030 |
Why?
|
Electroconvulsive Therapy | 1 | 1995 | 24 | 0.030 |
Why?
|
Hepatitis B Surface Antigens | 1 | 1994 | 24 | 0.030 |
Why?
|
Integrin alpha5beta1 | 1 | 2014 | 13 | 0.030 |
Why?
|
Hepatitis B Antibodies | 1 | 1994 | 15 | 0.030 |
Why?
|
Brain Mapping | 2 | 1995 | 547 | 0.030 |
Why?
|
Fluorescent Antibody Technique | 1 | 2015 | 314 | 0.030 |
Why?
|
Syk Kinase | 1 | 2014 | 6 | 0.030 |
Why?
|
Histone Deacetylase Inhibitors | 1 | 2015 | 85 | 0.030 |
Why?
|
Immobilized Proteins | 1 | 2014 | 14 | 0.030 |
Why?
|
Acetylcholine | 2 | 1994 | 176 | 0.030 |
Why?
|
beta-Glucans | 1 | 2014 | 5 | 0.030 |
Why?
|
Video Recording | 1 | 2015 | 190 | 0.030 |
Why?
|
Nonmuscle Myosin Type IIA | 1 | 2014 | 5 | 0.030 |
Why?
|
Choline O-Acetyltransferase | 1 | 1994 | 23 | 0.030 |
Why?
|
CARD Signaling Adaptor Proteins | 1 | 2014 | 15 | 0.030 |
Why?
|
Acetylcholinesterase | 1 | 1994 | 47 | 0.030 |
Why?
|
Thiazolidines | 1 | 2014 | 17 | 0.030 |
Why?
|
Mucin-1 | 1 | 2014 | 44 | 0.030 |
Why?
|
Candida albicans | 1 | 2014 | 32 | 0.030 |
Why?
|
Microscopy, Atomic Force | 1 | 2014 | 51 | 0.030 |
Why?
|
Dyneins | 1 | 2014 | 14 | 0.030 |
Why?
|
RNA Interference | 1 | 2015 | 368 | 0.030 |
Why?
|
Huntingtin Protein | 1 | 2014 | 10 | 0.030 |
Why?
|
Cytoplasm | 1 | 2015 | 281 | 0.030 |
Why?
|
Sequence Alignment | 1 | 2015 | 350 | 0.030 |
Why?
|
Health Care Surveys | 2 | 2006 | 277 | 0.030 |
Why?
|
Autophagy-Related Proteins | 1 | 2014 | 20 | 0.030 |
Why?
|
Actinin | 1 | 2014 | 19 | 0.030 |
Why?
|
Gene Deletion | 2 | 2010 | 328 | 0.030 |
Why?
|
Interleukin-1beta | 1 | 2014 | 78 | 0.030 |
Why?
|
Optical Imaging | 1 | 2014 | 48 | 0.030 |
Why?
|
Pattern Recognition, Visual | 1 | 1995 | 151 | 0.030 |
Why?
|
Pandemics | 1 | 2020 | 735 | 0.030 |
Why?
|
Collateral Circulation | 1 | 1994 | 35 | 0.030 |
Why?
|
Prefrontal Cortex | 1 | 1995 | 129 | 0.030 |
Why?
|
Environment | 1 | 2015 | 219 | 0.030 |
Why?
|
Models, Animal | 1 | 2015 | 260 | 0.030 |
Why?
|
Neoplastic Cells, Circulating | 1 | 2014 | 69 | 0.030 |
Why?
|
Fibronectins | 1 | 2014 | 93 | 0.030 |
Why?
|
Rural Population | 1 | 1994 | 136 | 0.030 |
Why?
|
Bridged Bicyclo Compounds, Heterocyclic | 1 | 2014 | 75 | 0.030 |
Why?
|
Bacterial Vaccines | 1 | 1993 | 41 | 0.030 |
Why?
|
Heart Rate | 3 | 1994 | 492 | 0.030 |
Why?
|
NADPH Oxidases | 1 | 2014 | 81 | 0.030 |
Why?
|
Receptors, Dopamine D3 | 1 | 1993 | 18 | 0.030 |
Why?
|
Proteoglycans | 1 | 2014 | 121 | 0.030 |
Why?
|
Organ Size | 1 | 2014 | 363 | 0.030 |
Why?
|
Chlorpromazine | 1 | 2013 | 14 | 0.030 |
Why?
|
Lod Score | 1 | 2013 | 151 | 0.030 |
Why?
|
Stress, Mechanical | 1 | 2014 | 248 | 0.030 |
Why?
|
Serologic Tests | 1 | 2013 | 41 | 0.030 |
Why?
|
Anti-Bacterial Agents | 1 | 2018 | 739 | 0.030 |
Why?
|
Chromosomes, Human, Pair 15 | 1 | 2013 | 63 | 0.030 |
Why?
|
Receptors, Adrenergic | 1 | 1993 | 15 | 0.030 |
Why?
|
Lysosomes | 1 | 2014 | 104 | 0.030 |
Why?
|
Cytomegalovirus | 1 | 2013 | 76 | 0.030 |
Why?
|
Mechanotransduction, Cellular | 1 | 2014 | 77 | 0.030 |
Why?
|
Sexual Partners | 1 | 1994 | 93 | 0.030 |
Why?
|
Herpesvirus 2, Human | 1 | 2013 | 45 | 0.030 |
Why?
|
Aortic Valve Insufficiency | 1 | 2014 | 129 | 0.030 |
Why?
|
Yohimbine | 1 | 1993 | 7 | 0.030 |
Why?
|
Perfusion | 1 | 2013 | 202 | 0.030 |
Why?
|
Disruptive, Impulse Control, and Conduct Disorders | 1 | 1997 | 276 | 0.030 |
Why?
|
Brain Damage, Chronic | 1 | 1993 | 26 | 0.030 |
Why?
|
Propensity Score | 1 | 2013 | 136 | 0.030 |
Why?
|
Helicobacter pylori | 1 | 2013 | 35 | 0.030 |
Why?
|
Genetic Testing | 2 | 2013 | 534 | 0.030 |
Why?
|
Asperger Syndrome | 1 | 2012 | 4 | 0.030 |
Why?
|
Chromatography, Gel | 2 | 1994 | 103 | 0.030 |
Why?
|
Feasibility Studies | 1 | 2015 | 751 | 0.030 |
Why?
|
Prosthesis Failure | 1 | 2013 | 111 | 0.030 |
Why?
|
Infusions, Intravenous | 1 | 2013 | 429 | 0.030 |
Why?
|
Contraception | 1 | 1994 | 88 | 0.030 |
Why?
|
Adenosine Triphosphate | 1 | 2014 | 312 | 0.030 |
Why?
|
Lymphoma, Non-Hodgkin | 1 | 1995 | 261 | 0.030 |
Why?
|
Body Temperature Regulation | 1 | 1992 | 56 | 0.030 |
Why?
|
Receptors, Cell Surface | 1 | 2014 | 286 | 0.030 |
Why?
|
Lipid Metabolism, Inborn Errors | 1 | 1992 | 8 | 0.030 |
Why?
|
Hematopoietic Stem Cell Transplantation | 1 | 1999 | 877 | 0.030 |
Why?
|
DNA Primers | 1 | 1993 | 542 | 0.030 |
Why?
|
Base Sequence | 2 | 1993 | 2327 | 0.030 |
Why?
|
Sexually Transmitted Diseases | 1 | 1994 | 91 | 0.030 |
Why?
|
Gadolinium DTPA | 1 | 2013 | 261 | 0.030 |
Why?
|
Protein-Tyrosine Kinases | 1 | 2014 | 302 | 0.030 |
Why?
|
Prosthesis Design | 1 | 2013 | 276 | 0.030 |
Why?
|
Antigens | 1 | 1993 | 228 | 0.030 |
Why?
|
Peroxidase | 1 | 2012 | 51 | 0.030 |
Why?
|
Breast | 1 | 2014 | 286 | 0.030 |
Why?
|
Endoplasmic Reticulum | 1 | 2014 | 250 | 0.030 |
Why?
|
Carbon Disulfide | 1 | 1972 | 1 | 0.030 |
Why?
|
Rats, Sprague-Dawley | 1 | 2015 | 1214 | 0.030 |
Why?
|
Transfection | 1 | 2014 | 894 | 0.030 |
Why?
|
Centrifugation, Density Gradient | 1 | 2012 | 112 | 0.030 |
Why?
|
Amino Acid Substitution | 1 | 2013 | 339 | 0.030 |
Why?
|
Poland | 1 | 2011 | 17 | 0.030 |
Why?
|
Autophagy | 1 | 2014 | 148 | 0.030 |
Why?
|
Netherlands | 1 | 2011 | 19 | 0.030 |
Why?
|
Neutralization Tests | 1 | 1992 | 77 | 0.030 |
Why?
|
Linear Models | 2 | 2008 | 419 | 0.030 |
Why?
|
Depression, Chemical | 1 | 1991 | 29 | 0.030 |
Why?
|
Speech Disorders | 1 | 1991 | 18 | 0.030 |
Why?
|
Adiponectin | 1 | 2011 | 24 | 0.030 |
Why?
|
Plaque, Amyloid | 2 | 2005 | 56 | 0.030 |
Why?
|
Body Constitution | 2 | 2002 | 26 | 0.030 |
Why?
|
Fluorescence | 1 | 2011 | 102 | 0.030 |
Why?
|
Protein Stability | 1 | 2011 | 99 | 0.030 |
Why?
|
Oxazepam | 1 | 1991 | 3 | 0.030 |
Why?
|
Disability Evaluation | 2 | 2003 | 136 | 0.030 |
Why?
|
Proteins | 1 | 1997 | 777 | 0.030 |
Why?
|
Genetic Linkage | 1 | 2013 | 623 | 0.030 |
Why?
|
Benztropine | 1 | 1991 | 4 | 0.030 |
Why?
|
Catalysis | 1 | 2011 | 203 | 0.030 |
Why?
|
Memory, Short-Term | 1 | 1995 | 220 | 0.030 |
Why?
|
Fluorescence Resonance Energy Transfer | 1 | 2011 | 94 | 0.030 |
Why?
|
Biomechanical Phenomena | 1 | 2013 | 456 | 0.030 |
Why?
|
Reactive Oxygen Species | 1 | 2014 | 477 | 0.030 |
Why?
|
Sequence Analysis, DNA | 1 | 2014 | 852 | 0.030 |
Why?
|
Stroke Volume | 1 | 2013 | 452 | 0.020 |
Why?
|
Family | 1 | 1993 | 311 | 0.020 |
Why?
|
Prostaglandins | 1 | 1991 | 42 | 0.020 |
Why?
|
Indomethacin | 1 | 1991 | 59 | 0.020 |
Why?
|
Glutamine | 1 | 1991 | 75 | 0.020 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 1992 | 376 | 0.020 |
Why?
|
Colorectal Neoplasms | 1 | 2018 | 924 | 0.020 |
Why?
|
Herpesvirus 1, Human | 1 | 2013 | 244 | 0.020 |
Why?
|
Mice, Knockout | 1 | 2015 | 1910 | 0.020 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2014 | 683 | 0.020 |
Why?
|
Cattle | 2 | 1982 | 374 | 0.020 |
Why?
|
Cytochalasin D | 1 | 2010 | 14 | 0.020 |
Why?
|
Dexamethasone | 1 | 1992 | 326 | 0.020 |
Why?
|
Birth Weight | 1 | 1970 | 144 | 0.020 |
Why?
|
Transcription, Genetic | 1 | 2015 | 1127 | 0.020 |
Why?
|
Pregnancy | 3 | 2013 | 2882 | 0.020 |
Why?
|
Critical Care | 1 | 2013 | 368 | 0.020 |
Why?
|
Carcinoma, Squamous Cell | 1 | 1997 | 1075 | 0.020 |
Why?
|
Recombinant Fusion Proteins | 1 | 2011 | 555 | 0.020 |
Why?
|
Amyloid beta-Peptides | 1 | 1991 | 203 | 0.020 |
Why?
|
Endosomes | 1 | 2010 | 75 | 0.020 |
Why?
|
Protein Biosynthesis | 1 | 1992 | 378 | 0.020 |
Why?
|
Extracellular Signal-Regulated MAP Kinases | 1 | 2010 | 115 | 0.020 |
Why?
|
Radioimmunoassay | 3 | 1994 | 155 | 0.020 |
Why?
|
Pollen | 1 | 1990 | 79 | 0.020 |
Why?
|
Endothelium | 1 | 2009 | 59 | 0.020 |
Why?
|
Brachial Artery | 1 | 2009 | 36 | 0.020 |
Why?
|
Waist-Hip Ratio | 1 | 2009 | 18 | 0.020 |
Why?
|
Plant Proteins | 1 | 1990 | 131 | 0.020 |
Why?
|
Vasodilation | 1 | 2009 | 96 | 0.020 |
Why?
|
Endocytosis | 1 | 2010 | 177 | 0.020 |
Why?
|
Bone and Bones | 2 | 2001 | 264 | 0.020 |
Why?
|
Electroencephalography | 1 | 1993 | 707 | 0.020 |
Why?
|
Bayes Theorem | 1 | 2010 | 360 | 0.020 |
Why?
|
Puerto Rico | 1 | 2008 | 31 | 0.020 |
Why?
|
Societies, Pharmaceutical | 1 | 2008 | 1 | 0.020 |
Why?
|
Myocardial Contraction | 2 | 2004 | 244 | 0.020 |
Why?
|
Models, Statistical | 1 | 2012 | 574 | 0.020 |
Why?
|
Equipment Design | 1 | 2010 | 405 | 0.020 |
Why?
|
Isoelectric Point | 1 | 1988 | 16 | 0.020 |
Why?
|
Heparin | 1 | 2009 | 175 | 0.020 |
Why?
|
Voluntary Health Agencies | 1 | 2008 | 5 | 0.020 |
Why?
|
Drosophila Proteins | 1 | 2013 | 486 | 0.020 |
Why?
|
Spectrophotometry | 1 | 1988 | 106 | 0.020 |
Why?
|
Cell Proliferation | 1 | 2014 | 1571 | 0.020 |
Why?
|
Platelet Aggregation | 1 | 2007 | 44 | 0.020 |
Why?
|
Bias | 1 | 2008 | 127 | 0.020 |
Why?
|
Growth Hormone | 1 | 1988 | 97 | 0.020 |
Why?
|
Psychopathology | 1 | 2007 | 29 | 0.020 |
Why?
|
Plasma | 2 | 1965 | 50 | 0.020 |
Why?
|
Interdisciplinary Communication | 1 | 2008 | 130 | 0.020 |
Why?
|
Electron Transport Complex IV | 2 | 1998 | 47 | 0.020 |
Why?
|
Seasons | 1 | 1989 | 223 | 0.020 |
Why?
|
Interleukins | 1 | 2008 | 130 | 0.020 |
Why?
|
Promoter Regions, Genetic | 1 | 2011 | 933 | 0.020 |
Why?
|
Flow Cytometry | 1 | 2009 | 676 | 0.020 |
Why?
|
Amino Acids | 1 | 1988 | 252 | 0.020 |
Why?
|
Glomerular Filtration Rate | 1 | 2009 | 384 | 0.020 |
Why?
|
Oxidation-Reduction | 1 | 1988 | 373 | 0.020 |
Why?
|
Cooperative Behavior | 1 | 2008 | 174 | 0.020 |
Why?
|
Electrocardiography | 1 | 2009 | 478 | 0.020 |
Why?
|
Hydrogen-Ion Concentration | 1 | 1988 | 493 | 0.020 |
Why?
|
Thyrotropin | 1 | 1988 | 280 | 0.020 |
Why?
|
Cats | 1 | 2007 | 302 | 0.020 |
Why?
|
Quetiapine Fumarate | 1 | 2006 | 4 | 0.020 |
Why?
|
Mortality | 1 | 2008 | 148 | 0.020 |
Why?
|
Genomic Imprinting | 1 | 2006 | 33 | 0.020 |
Why?
|
Auscultation | 1 | 1986 | 4 | 0.020 |
Why?
|
Sex Characteristics | 1 | 2009 | 318 | 0.020 |
Why?
|
Intracranial Embolism and Thrombosis | 1 | 1986 | 14 | 0.020 |
Why?
|
Rupture, Spontaneous | 1 | 1986 | 43 | 0.020 |
Why?
|
False Negative Reactions | 1 | 1986 | 63 | 0.020 |
Why?
|
Magnetic Resonance Spectroscopy | 1 | 2007 | 318 | 0.020 |
Why?
|
Infant Food | 2 | 1980 | 11 | 0.020 |
Why?
|
Glucose | 1 | 2009 | 637 | 0.020 |
Why?
|
Liver Neoplasms, Experimental | 1 | 1986 | 27 | 0.020 |
Why?
|
Phenformin | 1 | 1965 | 5 | 0.020 |
Why?
|
Tolbutamide | 1 | 1965 | 16 | 0.020 |
Why?
|
Hyperprolactinemia | 1 | 2005 | 5 | 0.020 |
Why?
|
Homes for the Aged | 1 | 2005 | 26 | 0.020 |
Why?
|
Patient Satisfaction | 1 | 2009 | 449 | 0.020 |
Why?
|
Uterus | 1 | 1987 | 214 | 0.020 |
Why?
|
Wechsler Scales | 2 | 1995 | 21 | 0.020 |
Why?
|
Ketone Bodies | 1 | 1965 | 17 | 0.020 |
Why?
|
Blood Specimen Collection | 1 | 1965 | 27 | 0.020 |
Why?
|
Necrosis | 1 | 1985 | 204 | 0.020 |
Why?
|
Drug Therapy | 1 | 1965 | 70 | 0.020 |
Why?
|
Inappropriate ADH Syndrome | 1 | 2004 | 5 | 0.020 |
Why?
|
Cadaver | 1 | 2005 | 183 | 0.020 |
Why?
|
Body Water | 1 | 2004 | 35 | 0.020 |
Why?
|
Hybrid Cells | 2 | 1996 | 72 | 0.020 |
Why?
|
Methoxyhydroxyphenylglycol | 2 | 1994 | 18 | 0.020 |
Why?
|
Water-Electrolyte Balance | 1 | 2004 | 66 | 0.020 |
Why?
|
Dietary Sucrose | 1 | 2004 | 13 | 0.020 |
Why?
|
Precancerous Conditions | 1 | 1986 | 196 | 0.020 |
Why?
|
Hyperinsulinism | 1 | 2004 | 51 | 0.020 |
Why?
|
Diabetic Ketoacidosis | 1 | 2004 | 13 | 0.020 |
Why?
|
Tyrosine | 2 | 1997 | 133 | 0.020 |
Why?
|
Alkaline Phosphatase | 1 | 2003 | 132 | 0.010 |
Why?
|
Rats, Wistar | 1 | 2004 | 296 | 0.010 |
Why?
|
Musculoskeletal Diseases | 1 | 2003 | 34 | 0.010 |
Why?
|
Databases as Topic | 1 | 2003 | 92 | 0.010 |
Why?
|
Radiography, Thoracic | 1 | 1985 | 320 | 0.010 |
Why?
|
Enteral Nutrition | 1 | 2003 | 102 | 0.010 |
Why?
|
Drug Monitoring | 1 | 2004 | 118 | 0.010 |
Why?
|
Hip | 1 | 2002 | 18 | 0.010 |
Why?
|
Oxygen Consumption | 2 | 1995 | 239 | 0.010 |
Why?
|
Social Conditions | 1 | 2002 | 8 | 0.010 |
Why?
|
Digitalis | 1 | 2002 | 2 | 0.010 |
Why?
|
Delivery of Health Care | 1 | 2007 | 421 | 0.010 |
Why?
|
Torsades de Pointes | 1 | 2002 | 7 | 0.010 |
Why?
|
Accidents | 1 | 1981 | 8 | 0.010 |
Why?
|
Parity | 1 | 2002 | 93 | 0.010 |
Why?
|
Lumbar Vertebrae | 1 | 2002 | 148 | 0.010 |
Why?
|
Acetamides | 1 | 2001 | 26 | 0.010 |
Why?
|
Psychosocial Deprivation | 1 | 2001 | 4 | 0.010 |
Why?
|
Alleles | 1 | 2005 | 1126 | 0.010 |
Why?
|
Demography | 1 | 2002 | 177 | 0.010 |
Why?
|
Fertility | 1 | 1982 | 111 | 0.010 |
Why?
|
Pilot Projects | 2 | 1994 | 837 | 0.010 |
Why?
|
Hypromellose Derivatives | 1 | 2000 | 4 | 0.010 |
Why?
|
Poultry Products | 1 | 2000 | 2 | 0.010 |
Why?
|
Fish Products | 1 | 2000 | 3 | 0.010 |
Why?
|
Chorionic Gonadotropin | 1 | 2000 | 71 | 0.010 |
Why?
|
Goals | 1 | 2001 | 67 | 0.010 |
Why?
|
DNA Methylation | 1 | 2005 | 620 | 0.010 |
Why?
|
Caregivers | 1 | 2002 | 151 | 0.010 |
Why?
|
Temperature | 1 | 1981 | 395 | 0.010 |
Why?
|
Hemarthrosis | 1 | 2000 | 3 | 0.010 |
Why?
|
Horses | 1 | 2000 | 35 | 0.010 |
Why?
|
Medial Collateral Ligament, Knee | 1 | 2000 | 5 | 0.010 |
Why?
|
Chromatography, Gas | 1 | 1980 | 28 | 0.010 |
Why?
|
Contusions | 1 | 2000 | 9 | 0.010 |
Why?
|
Data Interpretation, Statistical | 1 | 2002 | 297 | 0.010 |
Why?
|
Evaluation Studies as Topic | 1 | 2000 | 274 | 0.010 |
Why?
|
Posterior Cruciate Ligament | 1 | 2000 | 12 | 0.010 |
Why?
|
Collateral Ligaments | 1 | 2000 | 11 | 0.010 |
Why?
|
Bone Remodeling | 1 | 2000 | 24 | 0.010 |
Why?
|
Oxazines | 1 | 1999 | 13 | 0.010 |
Why?
|
Rupture | 1 | 2000 | 62 | 0.010 |
Why?
|
Menisci, Tibial | 1 | 2000 | 25 | 0.010 |
Why?
|
Tibial Meniscus Injuries | 1 | 2000 | 19 | 0.010 |
Why?
|
Diclofenac | 1 | 1999 | 4 | 0.010 |
Why?
|
Tibia | 1 | 2000 | 82 | 0.010 |
Why?
|
Fractures, Bone | 1 | 2001 | 131 | 0.010 |
Why?
|
Saimiri | 1 | 1999 | 50 | 0.010 |
Why?
|
Anterior Cruciate Ligament | 1 | 2000 | 48 | 0.010 |
Why?
|
Cyclooxygenase 2 Inhibitors | 1 | 1999 | 33 | 0.010 |
Why?
|
Anterior Cruciate Ligament Injuries | 1 | 2000 | 40 | 0.010 |
Why?
|
Sulfones | 1 | 1999 | 42 | 0.010 |
Why?
|
Antigens, CD34 | 1 | 1999 | 158 | 0.010 |
Why?
|
Cyclooxygenase 2 | 1 | 1999 | 99 | 0.010 |
Why?
|
Arthroscopy | 1 | 2000 | 94 | 0.010 |
Why?
|
Femur | 1 | 2000 | 116 | 0.010 |
Why?
|
Transaminases | 1 | 1999 | 34 | 0.010 |
Why?
|
Growth | 1 | 1999 | 43 | 0.010 |
Why?
|
Sexual Maturation | 1 | 1999 | 35 | 0.010 |
Why?
|
Cytochrome-c Oxidase Deficiency | 1 | 1998 | 3 | 0.010 |
Why?
|
Ubiquinone | 1 | 1998 | 10 | 0.010 |
Why?
|
Mitochondrial Encephalomyopathies | 1 | 1998 | 5 | 0.010 |
Why?
|
Coenzymes | 1 | 1998 | 6 | 0.010 |
Why?
|
Community Mental Health Services | 1 | 1998 | 15 | 0.010 |
Why?
|
Education | 1 | 1999 | 58 | 0.010 |
Why?
|
Transplantation, Autologous | 1 | 1999 | 328 | 0.010 |
Why?
|
Diuretics | 1 | 1998 | 124 | 0.010 |
Why?
|
Electrophoresis | 1 | 1998 | 55 | 0.010 |
Why?
|
Entorhinal Cortex | 1 | 1998 | 15 | 0.010 |
Why?
|
Varicose Ulcer | 1 | 1977 | 6 | 0.010 |
Why?
|
Exercise Tolerance | 1 | 1998 | 48 | 0.010 |
Why?
|
Dysgammaglobulinemia | 1 | 1977 | 4 | 0.010 |
Why?
|
Cyclic AMP | 1 | 1998 | 273 | 0.010 |
Why?
|
Lipopolysaccharides | 1 | 1999 | 285 | 0.010 |
Why?
|
Presenilin-1 | 1 | 1998 | 100 | 0.010 |
Why?
|
Adrenergic beta-Antagonists | 1 | 1998 | 152 | 0.010 |
Why?
|
Multigene Family | 1 | 1998 | 202 | 0.010 |
Why?
|
Src Homology 2 Domain-Containing, Transforming Protein 1 | 1 | 1997 | 5 | 0.010 |
Why?
|
Shc Signaling Adaptor Proteins | 1 | 1997 | 6 | 0.010 |
Why?
|
Synaptophysin | 1 | 1997 | 11 | 0.010 |
Why?
|
Qa-SNARE Proteins | 1 | 1997 | 17 | 0.010 |
Why?
|
Immunologic Deficiency Syndromes | 1 | 1977 | 47 | 0.010 |
Why?
|
Phosphopyruvate Hydratase | 1 | 1997 | 39 | 0.010 |
Why?
|
Synaptosomal-Associated Protein 25 | 1 | 1997 | 14 | 0.010 |
Why?
|
Vanadates | 1 | 1997 | 29 | 0.010 |
Why?
|
3T3 Cells | 1 | 1997 | 94 | 0.010 |
Why?
|
Zinc | 1 | 1977 | 91 | 0.010 |
Why?
|
Cell Size | 1 | 1997 | 65 | 0.010 |
Why?
|
Communication Disorders | 1 | 1997 | 7 | 0.010 |
Why?
|
Protein Tyrosine Phosphatases | 1 | 1997 | 46 | 0.010 |
Why?
|
Walking | 1 | 1998 | 86 | 0.010 |
Why?
|
Neoplasms, Second Primary | 1 | 1999 | 252 | 0.010 |
Why?
|
Immunoassay | 1 | 1997 | 92 | 0.010 |
Why?
|
Exercise Test | 1 | 1998 | 164 | 0.010 |
Why?
|
Epidermal Growth Factor | 1 | 1997 | 119 | 0.010 |
Why?
|
Drug Resistance, Microbial | 1 | 1996 | 72 | 0.010 |
Why?
|
Genetic Techniques | 1 | 1997 | 72 | 0.010 |
Why?
|
Counseling | 1 | 1998 | 144 | 0.010 |
Why?
|
Personality Assessment | 1 | 1997 | 98 | 0.010 |
Why?
|
Neocortex | 1 | 1998 | 95 | 0.010 |
Why?
|
Life Tables | 1 | 1996 | 48 | 0.010 |
Why?
|
Nasopharynx | 1 | 1996 | 47 | 0.010 |
Why?
|
Iron | 1 | 1997 | 163 | 0.010 |
Why?
|
Value of Life | 1 | 1996 | 22 | 0.010 |
Why?
|
In Situ Hybridization | 1 | 1997 | 307 | 0.010 |
Why?
|
Dementia, Multi-Infarct | 1 | 1996 | 1 | 0.010 |
Why?
|
Microbial Sensitivity Tests | 1 | 1996 | 142 | 0.010 |
Why?
|
Cholecystokinin | 1 | 1996 | 15 | 0.010 |
Why?
|
Vasoactive Intestinal Peptide | 1 | 1996 | 15 | 0.010 |
Why?
|
Consumer Product Safety | 1 | 1996 | 11 | 0.010 |
Why?
|
Markov Chains | 1 | 1996 | 125 | 0.010 |
Why?
|
Life Expectancy | 1 | 1996 | 85 | 0.010 |
Why?
|
Occipital Lobe | 1 | 1996 | 24 | 0.010 |
Why?
|
Chemoprevention | 1 | 1996 | 91 | 0.010 |
Why?
|
Biopsy | 1 | 2000 | 1160 | 0.010 |
Why?
|
Corticotropin-Releasing Hormone | 1 | 1996 | 44 | 0.010 |
Why?
|
Graft Survival | 1 | 1999 | 883 | 0.010 |
Why?
|
Costs and Cost Analysis | 1 | 1996 | 153 | 0.010 |
Why?
|
Microscopy | 1 | 1996 | 87 | 0.010 |
Why?
|
Haplorhini | 1 | 1995 | 81 | 0.010 |
Why?
|
Wound Healing | 1 | 1977 | 342 | 0.010 |
Why?
|
Dosage Forms | 1 | 1995 | 7 | 0.010 |
Why?
|
Mitoxantrone | 1 | 1995 | 68 | 0.010 |
Why?
|
RNA, Ribosomal | 1 | 1995 | 60 | 0.010 |
Why?
|
Decision Support Techniques | 1 | 1996 | 160 | 0.010 |
Why?
|
Etoposide | 1 | 1995 | 196 | 0.010 |
Why?
|
Prednisone | 1 | 1995 | 255 | 0.010 |
Why?
|
Galanin | 1 | 1994 | 6 | 0.010 |
Why?
|
Heart Function Tests | 1 | 1994 | 30 | 0.010 |
Why?
|
Genes | 1 | 1995 | 305 | 0.010 |
Why?
|
Antibody Formation | 1 | 1994 | 171 | 0.010 |
Why?
|
Hypothalamus | 1 | 1994 | 79 | 0.010 |
Why?
|
Tissue Distribution | 1 | 1994 | 290 | 0.010 |
Why?
|
Discrimination Learning | 1 | 1994 | 63 | 0.010 |
Why?
|
Species Specificity | 1 | 1995 | 678 | 0.010 |
Why?
|
Stimulation, Chemical | 1 | 1993 | 63 | 0.010 |
Why?
|
Respiratory System | 1 | 1974 | 116 | 0.010 |
Why?
|
Schizophrenic Language | 1 | 1992 | 2 | 0.010 |
Why?
|
Hallucinations | 1 | 1992 | 27 | 0.010 |
Why?
|
Borderline Personality Disorder | 1 | 1993 | 33 | 0.010 |
Why?
|
Affective Symptoms | 1 | 1992 | 47 | 0.010 |
Why?
|
Mental Processes | 1 | 1992 | 31 | 0.010 |
Why?
|
Textile Industry | 1 | 1972 | 2 | 0.010 |
Why?
|
Social Isolation | 1 | 1992 | 67 | 0.010 |
Why?
|
Psychoses, Substance-Induced | 1 | 1972 | 6 | 0.010 |
Why?
|
Acidosis, Lactic | 1 | 1992 | 12 | 0.010 |
Why?
|
RNA, Ribosomal, 16S | 1 | 1993 | 241 | 0.010 |
Why?
|
Dichotic Listening Tests | 1 | 1991 | 5 | 0.010 |
Why?
|
Hematologic Diseases | 1 | 1972 | 79 | 0.010 |
Why?
|
Eye Diseases | 1 | 1972 | 53 | 0.010 |
Why?
|
Occupational Diseases | 1 | 1972 | 55 | 0.010 |
Why?
|
Saccharomyces cerevisiae | 1 | 1994 | 434 | 0.010 |
Why?
|
Oxygen | 1 | 1996 | 725 | 0.010 |
Why?
|
Syndrome | 1 | 1992 | 445 | 0.010 |
Why?
|
Cerebrovascular Disorders | 1 | 1992 | 142 | 0.010 |
Why?
|
Methods | 1 | 1970 | 152 | 0.010 |
Why?
|
Crohn Disease | 1 | 1977 | 729 | 0.010 |
Why?
|
Minerals | 1 | 1970 | 22 | 0.010 |
Why?
|
Dietary Carbohydrates | 1 | 1970 | 38 | 0.010 |
Why?
|
Intubation, Gastrointestinal | 1 | 1970 | 31 | 0.010 |
Why?
|
Carbohydrate Metabolism, Inborn Errors | 1 | 1970 | 1 | 0.010 |
Why?
|
Galactosemias | 1 | 1970 | 3 | 0.010 |
Why?
|
Hepatitis A | 1 | 1970 | 3 | 0.010 |
Why?
|
Hepatolenticular Degeneration | 1 | 1970 | 19 | 0.010 |
Why?
|
Bile | 1 | 1970 | 57 | 0.010 |
Why?
|
Auditory Perception | 1 | 1991 | 96 | 0.010 |
Why?
|
Skin Diseases | 1 | 1972 | 166 | 0.010 |
Why?
|
Glycogen | 1 | 1970 | 59 | 0.010 |
Why?
|
Chromatography, Affinity | 1 | 1990 | 81 | 0.010 |
Why?
|
Breast Feeding | 1 | 1970 | 91 | 0.010 |
Why?
|
Antibody Specificity | 1 | 1990 | 129 | 0.010 |
Why?
|
Chromosome Mapping | 1 | 1993 | 1073 | 0.010 |
Why?
|
Lung Diseases | 1 | 1972 | 263 | 0.010 |
Why?
|
Immunoglobulin E | 1 | 1990 | 143 | 0.010 |
Why?
|
Cystic Fibrosis | 1 | 1970 | 112 | 0.010 |
Why?
|
Water | 1 | 1970 | 274 | 0.010 |
Why?
|
Hypersensitivity | 1 | 1990 | 152 | 0.010 |
Why?
|
Blotting, Western | 1 | 1990 | 779 | 0.010 |
Why?
|
Visual Perception | 1 | 1991 | 319 | 0.000 |
Why?
|
Mice, Inbred BALB C | 1 | 1990 | 1044 | 0.000 |
Why?
|
Hydroxymethylglutaryl-CoA-Reductases, NADP-dependent | 1 | 1987 | 2 | 0.000 |
Why?
|
Mevalonic Acid | 1 | 1987 | 13 | 0.000 |
Why?
|
Phosphoprotein Phosphatases | 1 | 1987 | 57 | 0.000 |
Why?
|
Models, Genetic | 1 | 1992 | 926 | 0.000 |
Why?
|
Progesterone | 1 | 1987 | 107 | 0.000 |
Why?
|
2-Acetylaminofluorene | 1 | 1986 | 1 | 0.000 |
Why?
|
Diethylnitrosamine | 1 | 1986 | 7 | 0.000 |
Why?
|
gamma-Glutamyltransferase | 1 | 1986 | 16 | 0.000 |
Why?
|
Phenobarbital | 1 | 1986 | 33 | 0.000 |
Why?
|
Rats, Inbred Strains | 1 | 1986 | 312 | 0.000 |
Why?
|
Epithelium | 1 | 1987 | 317 | 0.000 |
Why?
|
Protein Kinases | 1 | 1987 | 208 | 0.000 |
Why?
|
Insemination, Artificial | 1 | 1982 | 16 | 0.000 |
Why?
|
Ketones | 1 | 1961 | 13 | 0.000 |
Why?
|
Calcium, Dietary | 1 | 1982 | 63 | 0.000 |
Why?
|
Pregnancy, Animal | 1 | 1982 | 57 | 0.000 |
Why?
|
Epinephrine | 1 | 1961 | 84 | 0.000 |
Why?
|
Phosphorus | 1 | 1982 | 117 | 0.000 |
Why?
|
Intestine, Small | 1 | 1977 | 303 | 0.000 |
Why?
|
New Mexico | 1 | 1974 | 1 | 0.000 |
Why?
|
Pneumonia, Pneumococcal | 1 | 1974 | 4 | 0.000 |
Why?
|
Staphylococcus | 1 | 1974 | 24 | 0.000 |
Why?
|
Sputum | 1 | 1974 | 33 | 0.000 |
Why?
|
Pseudomonas | 1 | 1974 | 51 | 0.000 |
Why?
|
Trachea | 1 | 1974 | 293 | 0.000 |
Why?
|
Sepsis | 1 | 1974 | 304 | 0.000 |
Why?
|
Lung | 1 | 1974 | 1165 | 0.000 |
Why?
|